<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Aerosolized prostacyclins for acute respiratory distress syndrome (ARDS) - Afshari, A - 2017 | Cochrane Library</title> <meta content="Aerosolized prostacyclins for acute respiratory distress syndrome (ARDS) - Afshari, A - 2017 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007733.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Aerosolized prostacyclins for acute respiratory distress syndrome (ARDS) - Afshari, A - 2017 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007733.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD007733.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Aerosolized prostacyclins for acute respiratory distress syndrome (ARDS)" name="citation_title"/> <meta content="Arash Afshari" name="citation_author"/> <meta content="Rigshospitalet, Copenhagen University Hospital" name="citation_author_institution"/> <meta content="arriba.a@gmail.com" name="citation_author_email"/> <meta content="Anders Bastholm Bille" name="citation_author"/> <meta content="Juliane Marie Centret, Rigshospitalet" name="citation_author_institution"/> <meta content="Mikkel Allingstrup" name="citation_author"/> <meta content="Rigshospitalet, Copenhagen University Hospital" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="7" name="citation_issue"/> <meta content="10.1002/14651858.CD007733.pub3" name="citation_doi"/> <meta content="2017" name="citation_date"/> <meta content="2017/08/14" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007733.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007733.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007733.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Acute Lung Injury [*drug therapy, mortality]; Aerosols; Anti‐Inflammatory Agents [*administration &amp; dosage]; Epoprostenol [*administration &amp; dosage]; Respiratory Distress Syndrome [*drug therapy, mortality]; Vasodilator Agents [*administration &amp; dosage]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007733.pub3&amp;doi=10.1002/14651858.CD007733.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007733.pub3&amp;doi=10.1002/14651858.CD007733.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007733.pub3&amp;doi=10.1002/14651858.CD007733.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007733.pub3&amp;doi=10.1002/14651858.CD007733.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007733.pub3&amp;doi=10.1002/14651858.CD007733.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007733.pub3&amp;doi=10.1002/14651858.CD007733.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007733.pub3&amp;doi=10.1002/14651858.CD007733.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007733.pub3&amp;doi=10.1002/14651858.CD007733.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007733.pub3&amp;doi=10.1002/14651858.CD007733.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007733.pub3&amp;doi=10.1002/14651858.CD007733.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007733.pub3&amp;doi=10.1002/14651858.CD007733.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007733.pub3&amp;doi=10.1002/14651858.CD007733.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007733.pub3&amp;doi=10.1002/14651858.CD007733.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007733.pub3&amp;doi=10.1002/14651858.CD007733.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007733.pub3&amp;doi=10.1002/14651858.CD007733.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007733.pub3&amp;doi=10.1002/14651858.CD007733.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007733.pub3&amp;doi=10.1002/14651858.CD007733.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007733.pub3&amp;doi=10.1002/14651858.CD007733.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007733.pub3&amp;doi=10.1002/14651858.CD007733.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007733.pub3&amp;doi=10.1002/14651858.CD007733.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007733.pub3&amp;doi=10.1002/14651858.CD007733.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007733.pub3&amp;doi=10.1002/14651858.CD007733.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007733.pub3&amp;doi=10.1002/14651858.CD007733.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="Nio3SV1W";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD007733\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD007733\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007733\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007733\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","ru","ms","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD007733.pub3",title:"Aerosolized prostacyclins for acute respiratory distress syndrome (ARDS)",firstPublishedDate:"Aug 14, 2017 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Emergency and Critical Care Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=Nio3SV1W&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007733.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD007733.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD007733.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD007733.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007733.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD007733.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD007733.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD007733.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD007733.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD007733.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD007733.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD007733.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD007733.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD007733.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>3304 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD007733.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007733.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007733.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007733.pub3/full#CD007733-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007733.pub3/full#CD007733-sec-0070"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007733.pub3/full#CD007733-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007733.pub3/full#CD007733-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007733.pub3/full#CD007733-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007733.pub3/full#CD007733-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007733.pub3/full#CD007733-sec-0047"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007733.pub3/full#CD007733-sec-0065"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD007733.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007733.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007733.pub3/appendices#CD007733-sec-0074"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007733.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007733.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007733.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007733.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD007733.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD007733.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD007733.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2018 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD007733.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Aerosolized prostacyclins for acute respiratory distress syndrome (ARDS)</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007733.pub3/information#CD007733-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Arash Afshari</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007733.pub3/information#CD007733-cr-0003">Anders Bastholm Bille</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007733.pub3/information#CD007733-cr-0004">Mikkel Allingstrup</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD007733.pub3/information/en#CD007733-sec-0090">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 14 August 2017 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD007733.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD007733.pub3">https://doi.org/10.1002/14651858.CD007733.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD007733-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD007733-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD007733-abs-0006">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD007733-abs-0008">فارسی</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD007733-abs-0001" lang="en"> <section id="CD007733-sec-0001"> <h3 class="title" id="CD007733-sec-0001">Background</h3> <p>Acute respiratory distress syndrome (ARDS) is a critical condition that is associated with high mortality and morbidity. Aerosolized prostacyclin has been used to improve oxygenation despite the limited evidence available so far. </p> <p>This review was originally published in 2010 and updated in 2017.</p> </section> <section id="CD007733-sec-0002"> <h3 class="title" id="CD007733-sec-0002">Objectives</h3> <p>To assess the benefits and harms of aerosolized prostacyclin in adults and children with ARDS. </p> </section> <section id="CD007733-sec-0003"> <h3 class="title" id="CD007733-sec-0003">Search methods</h3> <p>In this update, we searched CENTRAL (2017, Issue 4); MEDLINE (OvidSP), Embase (OvidSP), ISI BIOSIS Previews, ISI Web of Science, LILACS, CINAHL (EBSCOhost), and three trials registers. We handsearched the reference lists of the latest reviews, randomized and non‐randomized trials, and editorials, and cross‐checked them with our search of MEDLINE. We contacted the main authors of included studies to request any missed, unreported or ongoing studies. The search was run from inception to 5 May 2017. </p> </section> <section id="CD007733-sec-0004"> <h3 class="title" id="CD007733-sec-0004">Selection criteria</h3> <p>We included all randomized controlled trials (RCTs), irrespective of publication status, date of publication, blinding status, outcomes published or language. We contacted trial investigators and study authors to retrieve relevant and missing data. </p> </section> <section id="CD007733-sec-0005"> <h3 class="title" id="CD007733-sec-0005">Data collection and analysis</h3> <p>Three authors independently abstracted data and resolved any disagreements by discussion. Our primary outcome measure was all‐cause mortality. We planned to perform subgroup and sensitivity analyses to assess the effect of aerosolized prostacyclin in adults and children, and on various clinical and physiological outcomes. We assessed the risk of bias through assessment of methodological trial components and the risk of random error through trial sequential analysis. </p> </section> <section id="CD007733-sec-0006"> <h3 class="title" id="CD007733-sec-0006">Main results</h3> <p>We included two RCTs with 81 participants.</p> <p>One RCT involved 14 critically ill children with ARDS (very low quality of evidence), and one RCT involved 67 critically ill adults (very low quality evidence). </p> <p>Only one RCT (paediatric trial) provided data on mortality and found no difference between intervention and control. However, this trial was eligible for meta‐analysis due to a cross‐over design. </p> <p>We assessed the benefits and harms of aerosolized prostacyclin. One RCT found no difference in improvement of partial pressure of oxygen in arterial blood/fraction of inspired oxygen (PaO<sub>2</sub>/FiO<sub>2</sub>) ratio (mean difference (MD) ‐25.35, 95% confidence interval (CI) ‐60.48 to 9.78; P = 0.16; 67 participants, very low quality evidence). </p> <p>There were no adverse events such as bleeding or organ dysfunction in any of the included trials. Due to the limited number of RCTs, we were unable to perform the prespecified subgroup and sensitivity analyses or trial sequential analysis. </p> </section> <section id="CD007733-sec-0007"> <h3 class="title" id="CD007733-sec-0007">Authors' conclusions</h3> <p>We are unable to tell from our results whether the intervention has an important effect on mortality because the results were too imprecise to rule out a small or no effect. Therefore, no current evidence supports or refutes the routine use of aerosolized prostacyclin for people with ARDS. There is an urgent need for more RCTs. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD007733-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD007733-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD007733-abs-0003">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD007733-abs-0007">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD007733-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ms#CD007733-abs-0005">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ru#CD007733-abs-0004">Русский</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD007733-abs-0002" lang="en"> <h3>Aerosols of prostacyclin for management of acute respiratory distress syndrome (ARDS)</h3> <p><b>Background</b> </p> <p>Acute respiratory distress syndrome (ARDS) results in low oxygen levels in the blood and can develop when fluid builds up in the lungs because of inflammation. A direct or indirect injury to the lungs can cause ARDS in children and adults. Such injuries include sepsis (a serious condition where the body responds to infection by injuring to its own tissues and organs), viral infections, burns, massive blood transfusions, multiple trauma, entry of stomach contents into respiratory system, inflammation of the pancreas, inhalation injury, drug overdose and near drowning. ARDS is a major cause of death in critically ill people. </p> <p>Prostacyclin can be administered as an aerosol to critically ill adults and children with ARDS to increase the blood oxygen levels and improve survival. It is a naturally occurring prostaglandin that relaxes blood vessels, stops blood platelets from clotting (antiplatelet aggregation) and has anti‐inflammatory properties in the lungs. </p> <p><b>Study characteristics</b> </p> <p>This review was updated in 2017. We included two randomized controlled trials (RCT; clinical studies where people are randomly put into one of two or more treatment groups), one involving 14 critically ill children with ARDS and one involving 67 critically ill adults with ARDS. The trials did not measure severity of illness, resolution of organ dysfunction, length of stay in intensive care unit or hospital, and quality of life. The study authors did not report side effects such as bleeding, organ dysfunction, airway reactivity or side effects unrelated to the intervention. </p> <p><b>Study funding source</b> </p> <p>None of the included trials reported receiving money from drug companies.</p> <p><b>Key results</b> </p> <p>Only the RCT involving children provided data on deaths, with no clear difference with and without prostacyclin. </p> <p>The RCT in adults reported a trend towards improved blood oxygen levels, for participants who were treated with alprostadil (prostaglandin E1). </p> <p>Therefore, we could not identify a clear advantage of the use of aerosolized prostacyclin in critically ill children or adults with low blood oxygen levels. </p> <p><b>Quality of the evidence</b> </p> <p>The quality of the evidence was very low because of the limited number of participants and poor trial design. The RCT involving children used a cross‐over design where one group received aerosolized prostacyclin first and the other group received saline (salt solution). They then changed over to the alternate treatment. There was insufficient information on the effect on death in both trials. </p> <p>We conclude that there is a need for a large‐scale clinical trial with low risk of misleading information to investigate the advantages and harms of prostacyclin for critically ill people. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD007733-sec-0070" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD007733-sec-0070"></div> <h3 class="title" id="CD007733-sec-0071">Implications for practice</h3> <section id="CD007733-sec-0071"> <p>There is insufficient evidence to support the routine use of aerosolized prostacyclin in people with acute respiratory distress syndrome (ARDS) and, equally important, insufficient information on the effect on mortality is available. Despite signs of improved oxygenation, there is no statistically significant effect on mortality or other clinical outcomes since only two RCTs have been carried out (<a href="./references#CD007733-bbs2-0001" title="DahlemP , vanAalderenWM , deNeefM , DijkgraafMG , BosAP . Randomized controlled trial of aerosolized prostacyclin therapy in children with acute lung injury. Critical Care Medicine2004;32(4):1055‐60. [PUBMED: 15071401] ">Dahlem 2004</a>; <a href="./references#CD007733-bbs2-0002" title="SiddiquiS , SalahuddinN , ZubairS , YousufM , AzamI , GilaniAH . Use of inhaled PGE1 to improve diastolic dysfunction, LVEDP, pulmonary hypertension and hypoxia in ARDS ‐ a randomised clinical trial. Open Journal of Anesthesiology2013;3(2):109‐15. [DOI: 10.4236/ojanes.2013.32027] ">Siddiqui 2013</a>). For the same reason, the overall quality of evidence is very low for mortality, partial pressure of oxygen in arterial blood/fraction of inspired oxygen (PaO<sub>2</sub>/FiO<sub>2</sub>) ratio and adverse events, based on the GRADE method of assessment. </p> </section> <h3 class="title" id="CD007733-sec-0072">Implications for research</h3> <section id="CD007733-sec-0072"> <p>There is a need for large randomized trials with low risk of bias and an information size of up to several thousand participants (children as well as adults), to evaluate aerosolized prostacyclin before this intervention can be definitely rejected or accepted for use in critically ill patients with ARDS. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD007733-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD007733-sec-0008"></div> <div class="table" id="CD007733-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Aerosolized prostacyclin compared to placebo for acute respiratory distress syndrome (ARDS)</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>Aerosolized prostacyclin compared to placebo for acute respiratory distress syndrome (ARDS) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with ARDS </p> <p><b>Setting:</b> intensive care unit in the Netherlands and Pakistan </p> <p><b>Intervention:</b> aerosolized prostacyclin </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with aerosolized prostacyclin</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Mortality</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.50<br/> (0.17 to 12.94) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>14<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>1,2,3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Only 1 small paediatric trial with cross‐over design provided mortality data (<a href="./references#CD007733-bbs2-0001" title="DahlemP , vanAalderenWM , deNeefM , DijkgraafMG , BosAP . Randomized controlled trial of aerosolized prostacyclin therapy in children with acute lung injury. Critical Care Medicine2004;32(4):1055‐60. [PUBMED: 15071401] ">Dahlem 2004</a>). Thus, no meta‐analysis carried out. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>167 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>250 per 1000<br/> (28 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PaO<sub>2</sub>/FiO<sub>2</sub> ratio<sup>5</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 25.35 lower<br/> (60.48 lower to 9.78 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Only 1 trial provided data (<a href="./references#CD007733-bbs2-0002" title="SiddiquiS , SalahuddinN , ZubairS , YousufM , AzamI , GilaniAH . Use of inhaled PGE1 to improve diastolic dysfunction, LVEDP, pulmonary hypertension and hypoxia in ARDS ‐ a randomised clinical trial. Open Journal of Anesthesiology2013;3(2):109‐15. [DOI: 10.4236/ojanes.2013.32027] ">Siddiqui 2013</a>). Thus, no meta‐analysis was carried out. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Improvement in mean pulmonary arterial pressure</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data is available for meta‐analysis (<a href="./references#CD007733-sec-0097" title="">Characteristics of included studies</a>, <a href="./references#CD007733-bbs2-0002" title="SiddiquiS , SalahuddinN , ZubairS , YousufM , AzamI , GilaniAH . Use of inhaled PGE1 to improve diastolic dysfunction, LVEDP, pulmonary hypertension and hypoxia in ARDS ‐ a randomised clinical trial. Open Journal of Anesthesiology2013;3(2):109‐15. [DOI: 10.4236/ojanes.2013.32027] ">Siddiqui 2013</a>) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events<sup>7</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81</p> <p>(2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>8</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Only descriptive assessment of safety with no available data to carry out meaningful analyses (<a href="./references#CD007733-bbs2-0001" title="DahlemP , vanAalderenWM , deNeefM , DijkgraafMG , BosAP . Randomized controlled trial of aerosolized prostacyclin therapy in children with acute lung injury. Critical Care Medicine2004;32(4):1055‐60. [PUBMED: 15071401] ">Dahlem 2004</a>; <a href="./references#CD007733-bbs2-0002" title="SiddiquiS , SalahuddinN , ZubairS , YousufM , AzamI , GilaniAH . Use of inhaled PGE1 to improve diastolic dysfunction, LVEDP, pulmonary hypertension and hypoxia in ARDS ‐ a randomised clinical trial. Open Journal of Anesthesiology2013;3(2):109‐15. [DOI: 10.4236/ojanes.2013.32027] ">Siddiqui 2013</a>). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>FiO<sub>2</sub>:</b> fraction of inspired oxygen; <b>MD:</b> mean difference; <b>PaO<sub>2</sub>:</b> partial pressure of oxygen in arterial blood; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Mortality at 28 to 30 days. </p> <p><sup>2</sup>Required information size for paediatric population depending on the level of heterogeneity adjustment was between 2897 (I<sub>2</sub> = 0) and 3862 (I<sub>2</sub> = 25%).<br/> <sup>3</sup>Required information size for the adult population depending on the same level of heterogeneity was between 1132 (I<sub>2</sub> = 0) and 1508 (I<sub>2</sub> = 25%). </p> <p><sup>4</sup>This outcome was downgraded from high to low quality of evidence due to limitations in design (small sample size, few events, cross‐over design) suggesting high likelihood of bias, indirectness of evidence and high probability of publication bias. (<a href="./references#CD007733-bbs2-0001" title="DahlemP , vanAalderenWM , deNeefM , DijkgraafMG , BosAP . Randomized controlled trial of aerosolized prostacyclin therapy in children with acute lung injury. Critical Care Medicine2004;32(4):1055‐60. [PUBMED: 15071401] ">Dahlem 2004</a>). </p> <p><sup>5</sup>Despite the fact that biochemical markers of clinical outcomes are often not included in SoF tables, we have chosen to include this outcomes since it is widely used in clinical practice to guide treatment. </p> <p><sup>6</sup>The outcome was downgraded two levels (from high to very low quality of evidence) for very serious imprecision due to small sample size, few events and wide 95% CI suggesting high likelihood of bias and indirectness of evidence. (<a href="./references#CD007733-bbs2-0002" title="SiddiquiS , SalahuddinN , ZubairS , YousufM , AzamI , GilaniAH . Use of inhaled PGE1 to improve diastolic dysfunction, LVEDP, pulmonary hypertension and hypoxia in ARDS ‐ a randomised clinical trial. Open Journal of Anesthesiology2013;3(2):109‐15. [DOI: 10.4236/ojanes.2013.32027] ">Siddiqui 2013</a>). </p> <p><sup>7</sup>Adverse events such as bleeding or organ dysfunction </p> <p><sup>8</sup>The outcome was downgraded two levels (from high to very low quality of evidence) for very serious imprecision due to small sample size and few events and since only descriptive assessment of safety and adverse events were provided in the included trials with no data being available for meta‐analyses. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD007733-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD007733-sec-0009"></div> <section id="CD007733-sec-0010"> <h3 class="title" id="CD007733-sec-0010">Description of the condition</h3> <p>Acute respiratory distress syndrome (ARDS) affects both children and adults. It is the result of an inflammatory process where the end‐organ affected by the inflammatory cascade is the lung and its alveolar‐capillary units (<a href="./references#CD007733-bbs2-0035" title="AndersonMR . Update on pediatric acute respiratory distress syndrome. Respiratory Care2003;48(3):261‐76. [PUBMED: 12667276] ">Anderson 2003</a>). ARDS is a complication of a direct (primary) or indirect (secondary) lung injury caused by burns, massive transfusions, multiple trauma, aspiration of gastric contents, pancreatitis, inhalation injury, nosocomial pneumonia, sepsis, drug overdose and near drowning (<a href="./references#CD007733-bbs2-0054" title="JainR , DalNogareA . Pharmacological therapy for acute respiratory distress syndrome. Mayo Clinic Proceedings2006;81(2):205‐12. [PUBMED: 16471076] ">Jain 2006</a>; <a href="./references#CD007733-bbs2-0076" title="WareLB , MatthayMA . The acute respiratory distress syndrome. New England Journal of Medicine2000;342(18):1334‐49. [PUBMED: 10793167] ">Ware 2000</a>). </p> <p>Since this review was first published (<a href="./references#CD007733-bbs2-0082" title="AfshariA , BrokJ , MøllerAM , WetterslevJ . Aerosolized prostacyclin for acute lung injury (ALI) and acute respiratory distress syndrome (ARDS). Cochrane Database of Systematic Reviews2010, Issue 8. [DOI: 10.1002/14651858.CD007733; PUBMED: 20687093] ">Afshari 2010</a>), the definition of acute respiratory failure has changed. ARDS and acute lung injury (ALI) in adults or children older than one month of age were initially defined by the American‐European Consensus Conference (AECC) in 1994 (<a href="./references#CD007733-bbs2-0038" title="BernardGR , ArtigasA , BrighamKL , CarletJ , FalkeK , HudsonL , et al. The American‐European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. American Journal of Respiratory and Critical Care Medicine1994;149(3 Pt 1):818‐24. [PUBMED: 7509706] ">Bernard 1994</a>). The ARDS Definition Task Force produced the latest definition and developed the Berlin definition (<a href="./references#CD007733-bbs2-0065" title="ARDS Definition Task Force, RanieriV , RubenfeldG , ThompsonB , FergusonN , CaldwellE , FanE , et al. Acute respiratory distress syndrome: the Berlin Definition. JAMA2012;307(23):2526‐33. [PUBMED: 22797452] ">Ranieri 2012</a>). </p> <p>According to the Berlin definition, ARDS is defined by:</p> <p> <ol id="CD007733-list-0001"> <li> <p>timing: within one week of a known clinical insult or new or worsening respiratory symptoms; </p> </li> <li> <p>chest imaging: bilateral opacities ‐ not fully explained by effusions, lobar/lung collapse or nodules; </p> </li> <li> <p>origin of oedema: respiratory failure not fully explained by cardiac failure or fluid overload. Need objective assessment (e.g. echocardiography) to exclude hydrostatic oedema if no risk factor present; </p> </li> <li> <p>oxygenation:</p> <ol id="CD007733-list-0002"> <li> <p>Mild: PaO<sub>2</sub>/FIO<sub>2</sub> greater than 200 mmHg to 300 mmHg with positive end expiratory pressure (PEEP) or continuous positive airway pressure 5 cm H<sub>2</sub>O or greater; </p> </li> <li> <p>Moderate: PaO<sub>2</sub>/FIO<sub>2</sub> greater than 100 mmHg to 200 mmHg or less with PEEP 5 cm H<sub>2</sub>O or greater; </p> </li> <li> <p>Severe: PaO<sub>2</sub>/FIO<sub>2</sub> 100 mmHg or less with PEEP 5 cm H<sub>2</sub>O or greater. </p> </li> </ol> </li> </ol> </p> <p>ARDS is among the leading causes of death in critically ill people (<a href="./references#CD007733-bbs2-0046" title="FröhlichS , MurphyN , RyanD , BoylanJ . Acute respiratory distress syndrome: current concepts and future directions. Anaesthesia and Intensive Care2013;41(4):463‐72. [PUBMED: 23808504] ">Fröhlich 2013</a>). <a href="./references#CD007733-bbs2-0075" title="VohwinkelC , HoeglS , EltzschigH . Hypoxia signaling during acute lung injury. Journal of Applied Physiology (Bethesda, Md. : 1985)2015;119(10):1157‐63. [PUBMED: 25977449] ">Vohwinkel 2015</a> estimates an incidence of approximately 200,000 people annually in the US alone. Worldwide, <a href="./references#CD007733-bbs2-0058" title="LuhrOR , AntonsenK , KarlssonM , AardalS , ThorsteinssonA , FrostellCG , et al. Incidence and mortality after acute respiratory failure and acute respiratory distress syndrome in Sweden, Denmark, and Iceland. The ARF Study Group. American Journal of Respiratory and Critical Care Medicine1999;159(6):1849‐61. [PUBMED: 10351930] ">Luhr 1999</a> and <a href="./references#CD007733-bbs2-0067" title="RubenfeldGD , CaldwellE , PeabodyE , WeaverJ , MartinDP , NeffM , et al. Incidence and outcomes of acute lung injury. New England Journal of Medicine2005;353(16):1685‐93. [PUBMED: 16236739] ">Rubenfeld 2005</a> reported the incidence to be between 14 and 86 people per 10,0000 per year in the general population. A report from Finland indicated a smaller incidence of ARDS of 10.6 per 100,000 per year for ALI (reported prior to 2012 definition of ARDS) and 5.0 per 100,000 per year for ARDS (<a href="./references#CD007733-bbs2-0057" title="LinkoR , OkkonenM , PettiläV , PerttiläJ , ParviainenI , RuokonenE , et al. Acute respiratory failure in intensive care units. FINNALI: a prospective cohort study. Intensive Care Medicine2009;35(8):1352‐61. [PUBMED: 19526218] ">Linko 2009</a>). Mortality has gradually dropped to current figures of 25% to 58% throughout the last 30 years due to improved treatment regimens (<a href="./references#CD007733-bbs2-0035" title="AndersonMR . Update on pediatric acute respiratory distress syndrome. Respiratory Care2003;48(3):261‐76. [PUBMED: 12667276] ">Anderson 2003</a>; <a href="./references#CD007733-bbs2-0059" title="MacCallumNS , EvansTW . Epidemiology of acute lung injury. Current Opinion in Critical Care2005;11(1):43‐9. [PUBMED: 15659944] ">MacCallum 2005</a>). One systematic review indicated a mortality rate of 44.0% (95% confidence interval (CI) 40.1% to 47.5%) from observational studies, and 36.2% (95% CI 32.1% to 40.5%) from randomized controlled trials (RCT) (<a href="./references#CD007733-bbs2-0061" title="PhuaJ , BadiaJR , AdhikariNK , FriedrichJO , FowlerRA , SinghJM , et al. Has mortality from acute respiratory distress syndrome decreased over time? A systematic review. American Journal of Respiratory and Critical Care Medicine2009;179(3):220‐7. [PUBMED: 19011152] ">Phua 2009</a>). </p> <p>In paediatric settings, evidence indicates that the incidence of ARDS is around 12 cases per 100,000 population per year (<a href="./references#CD007733-bbs2-0080" title="ZimmermanJJ , AkhtarSR , CaldwellE , RubenfeldGD . Incidence and outcomes of pediatric acute lung injury. Pediatrics2009;124(1):87‐95. [PUBMED: 19564287] ">Zimmerman 2009</a>). Inhospital mortality is around 18% to 23%, with pneumonia, aspiration and sepsis as the primary causes of the condition (<a href="./references#CD007733-bbs2-0041" title="DahlemP , vanAalderenWM , HamakerME , DijkgraafMG , BosAP . Incidence and short‐term outcome of acute lung injury in mechanically ventilated children. European Respiratory Journal2003;22(6):980‐5. [PUBMED: 14680089] ">Dahlem 2003</a>; <a href="./references#CD007733-bbs2-0042" title="DahlemP , vanAalderenWM , BosAP . Pediatric acute lung injury. Paediatric Respiratory Reviews2007;8(4):348‐62. [PUBMED: 18005903] ">Dahlem 2007</a>; <a href="./references#CD007733-bbs2-0045" title="FloriHR , GliddenDV , RutherfordGW , MatthayMA . Pediatric acute lung injury: prospective evaluation of risk factors associated with mortality. American Journal of Respiratory and Critical Care Medicine2005;171(9):995‐1001. [PUBMED: 15618461] ">Flori 2005</a>; <a href="./references#CD007733-bbs2-0080" title="ZimmermanJJ , AkhtarSR , CaldwellE , RubenfeldGD . Incidence and outcomes of pediatric acute lung injury. Pediatrics2009;124(1):87‐95. [PUBMED: 19564287] ">Zimmerman 2009</a>). </p> <p>Inflammatory injuries disrupt the capillary endothelium and alveolar epithelia leading to neutrophil invasion and alveolar oedema and collapse (exudative phase). The next stage (proliferative stage) occurs at days seven to 21 with initiation of lung repair and increased surfactant production. People experience dyspnoea and hypoxaemia at this stage, with or without ventilatory support. Some people may then proceed to the fibrotic stage with a long‐term need for ventilatory assist or oxygen therapy (<a href="./references#CD007733-bbs2-0076" title="WareLB , MatthayMA . The acute respiratory distress syndrome. New England Journal of Medicine2000;342(18):1334‐49. [PUBMED: 10793167] ">Ware 2000</a>). </p> <p>The worst prognosis is seen among people with sepsis or multiple organ failure, who are immunocompromised, and in whom oxygenation fails to improve after six days (<a href="./references#CD007733-bbs2-0072" title="TenHoorT , ManninoDM , MossM . Risk factors for ARDS in the United States: analysis of the 1993 National Mortality Followback Study. Chest2001;119(4):1179‐84. [PUBMED: 11296187] ">TenHoor 2001</a>; <a href="./references#CD007733-bbs2-0076" title="WareLB , MatthayMA . The acute respiratory distress syndrome. New England Journal of Medicine2000;342(18):1334‐49. [PUBMED: 10793167] ">Ware 2000</a>). Survivors tend to be young and their pulmonary function recovers gradually over one year (<a href="./references#CD007733-bbs2-0062" title="PiantadosiCA , SchwartzDA . The acute respiratory distress syndrome. Annals of Internal Medicine2004;141(6):460‐70. [PUBMED: 15381520] ">Piantadosi 2004</a>). Many adult survivors have long‐term abnormalities in pulmonary function and impaired quality of life (<a href="./references#CD007733-bbs2-0035" title="AndersonMR . Update on pediatric acute respiratory distress syndrome. Respiratory Care2003;48(3):261‐76. [PUBMED: 12667276] ">Anderson 2003</a>; <a href="./references#CD007733-bbs2-0036" title="AngusDC , MusthafaAA , ClermontG , GriffinMF , Linde‐ZwirbleWT , DremsizovTT , et al. Quality‐adjusted survival in the first year after the acute respiratory distress syndrome. American Journal of Respiratory and Critical Care Medicine2001;163(6):1389‐94. [PUBMED: 11371406] ">Angus 2001</a>). </p> </section> <section id="CD007733-sec-0011"> <h3 class="title" id="CD007733-sec-0011">Description of the intervention</h3> <p><b>Prostaglandins</b> are lipid mediators that are synthesized from essential fatty acids by cellular enzymes and have strong physiological properties. They have important effects on endothelium, platelet, uterine and mast cells and are found in virtually all tissues and organs. </p> <p><b>Prostacyclin (PGI<sub>2</sub>), generic name epoprostenol (brand name Flolan)</b> is a member of the family of lipid molecules known as eicosanoids. Prostacyclin is a naturally occurring prostaglandin that has vascular smooth muscle relaxant and anti‐inflammatory properties (it inhibits platelet aggregation and neutrophil adhesion). It is synthesized by vascular endothelial and smooth muscle cells within the lung and has an in vivo half‐life of three to six minutes (<a href="./references#CD007733-bbs2-0054" title="JainR , DalNogareA . Pharmacological therapy for acute respiratory distress syndrome. Mayo Clinic Proceedings2006;81(2):205‐12. [PUBMED: 16471076] ">Jain 2006</a>). Prostacyclin is a potent vasodilator of the systemic and pulmonary vasculature resulting in reduction of right and left heart afterload (<a href="./references#CD007733-bbs2-0071" title="SiobalM . Aerosolized prostacyclins. Respiratory Care2004;49(6):640‐52. [PUBMED: 15165299] ">Siobal 2004</a>) and can be administered by different routes such as: intravenous for pulmonary hypertension, and inhalational preparations for ARDS. Inhaled prostacyclin appears to improve oxygenation; lower pulmonary vascular resistance (PVR) and mean pulmonary arterial pressure (MPAP); and reduce pulmonary shunt fraction (<a href="./references#CD007733-bbs2-0071" title="SiobalM . Aerosolized prostacyclins. Respiratory Care2004;49(6):640‐52. [PUBMED: 15165299] ">Siobal 2004</a>). It might have potential benefits in resolving hypoxaemia from ARDS and in the treatment of pulmonary hypertension and right heart failure, similar to the indications for inhaled nitric oxide (INO) (<a href="./references#CD007733-bbs2-0071" title="SiobalM . Aerosolized prostacyclins. Respiratory Care2004;49(6):640‐52. [PUBMED: 15165299] ">Siobal 2004</a>). </p> <p><b>Iloprost</b> is a stable, synthetic analogue of prostacyclin. It has a plasma half‐life of 20 to 30 minutes, similar pulmonary and haemodynamic properties as prostacyclin and can be administered as an intravenous or inhalable solution (<a href="./references#CD007733-bbs2-0052" title="HillNS , PrestonIR , RobertsKE . Inhaled therapies for pulmonary hypertension. Respiratory Care2015;60(6):794‐802. [PUBMED: 26070575 ] ">Hill 2015</a>). </p> <p>During mechanical ventilation lasting from hours to several days, inhalable prostacyclins require continuous aerosolization with specific nebulizers or periodic nebulization, for example, several times a day using long‐acting prostacyclin (e.g. iloprost) (<a href="./references#CD007733-bbs2-0052" title="HillNS , PrestonIR , RobertsKE . Inhaled therapies for pulmonary hypertension. Respiratory Care2015;60(6):794‐802. [PUBMED: 26070575 ] ">Hill 2015</a>; <a href="./references#CD007733-bbs2-0070" title="SiobalMS , KalletRH , PittetJF , WarneckeEL , KraemerRW , VenkayyaRV , et al. Description and evaluation of a delivery system for aerosolized prostacyclin. Respiratory Care2003;48(8):742‐53. [PUBMED: 12890294] ">Siobal 2003</a>). </p> <p><b>Prostaglandin E<sub>1</sub> (PGE<sub>1</sub>), generic name alprostadil (brand name Prostin)</b> is a naturally occurring prostaglandin with anti‐inflammatory capabilities. PGE<sub>1</sub> is an arterial vasodilator, a platelet aggregation inhibitor, and stimulates intestinal and uterine smooth muscle (<a href="./references#CD007733-bbs2-0071" title="SiobalM . Aerosolized prostacyclins. Respiratory Care2004;49(6):640‐52. [PUBMED: 15165299] ">Siobal 2004</a>). It is mainly used to treat sexual dysfunction or as an intravenous treatment for neonates with congenital heart defects, to maintain patency of ductus arteriosus until surgery. Its half‐life is five to 10 minutes and it is primarily removed by the pulmonary vascular bed. PGE<sub>1</sub> leads to a decrease in MPAP, mean arterial pressure, PVR and systemic vascular resistance. It can also be used as an inhalable solution with the potential to improve oxygenation in people with severe ARDS (<a href="./references#CD007733-bbs2-0069" title="SchusterKM , AlouidorR , BarquistES . Nonventilatory interventions in the acute respiratory distress syndrome. Journal of Intensive Care Medicine2008;23(1):19‐32. [PUBMED: 18230633] ">Schuster 2008</a>). </p> </section> <section id="CD007733-sec-0012"> <h3 class="title" id="CD007733-sec-0012">How the intervention might work</h3> <p>Aerosolized prostacyclins are potent vasodilators which reduce pulmonary arterial hypertension, improve right‐heart function, redistribute pulmonary blood flow to ventilated segments of the lung with matching improvements in ventilation and perfusion to result in better oxygenation (<a href="./references#CD007733-bbs2-0052" title="HillNS , PrestonIR , RobertsKE . Inhaled therapies for pulmonary hypertension. Respiratory Care2015;60(6):794‐802. [PUBMED: 26070575 ] ">Hill 2015</a>). </p> <p>PGE<sub>1</sub> and prostacyclin seem to reduce obstruction of pulmonary microcirculation in ARDS and modulate the underlying inflammation due to their ability to reduce leukocyte adhesion, and antithrombotic and platelet disaggregation properties (<a href="./references#CD007733-bbs2-0079" title="WetzelRC . Aerosolized prostacyclin. In search of the ideal pulmonary vasodilator. Anesthesiology1995;82(6):1315‐7. [PUBMED: 7793644] ">Wetzel 1995</a>). Inhaled prostacyclins cause minimal systemic vasodilation and, due to minor transfer to the vascular system, they may even have systemic anti‐inflammatory and antithrombotic features and improve splanchnic oxygenation (<a href="./references#CD007733-bbs2-0012" title="EichelbrönnerO , ReineltH , WiedeckH , MezödyM , RossaintR , GeorgieffM , et al. Aerosolized prostacyclin and inhaled nitric oxide in septic shock ‐ different effects on splanchnic oxygenation?. Intensive Care Medicine1996;22(9):880‐7. [PUBMED: 8905421] ">Eichelbrönner 1996</a>; <a href="./references#CD007733-bbs2-0071" title="SiobalM . Aerosolized prostacyclins. Respiratory Care2004;49(6):640‐52. [PUBMED: 15165299] ">Siobal 2004</a>). However, the principle action of aerosolized prostacyclins is their property of selective vasodilation to reduce hypoxaemia. </p> <p>Inhaled prostacyclins may result in an increased ventilation/perfusion mismatch, decreased oxygenation, systemic hypotension, bleeding, flushing, headache, nausea, vomiting and chest pain (<a href="./references#CD007733-bbs2-0071" title="SiobalM . Aerosolized prostacyclins. Respiratory Care2004;49(6):640‐52. [PUBMED: 15165299] ">Siobal 2004</a>). However, there appear to be very few reported adverse effects from inhaled prostacyclins (<a href="./references#CD007733-bbs2-0071" title="SiobalM . Aerosolized prostacyclins. Respiratory Care2004;49(6):640‐52. [PUBMED: 15165299] ">Siobal 2004</a>). Prostacyclin solution may act as a potential irritant due to its very alkaline pH. Prostacyclins have no known toxic metabolites. </p> </section> <section id="CD007733-sec-0013"> <h3 class="title" id="CD007733-sec-0013">Why it is important to do this review</h3> <p>ARDS is characterized by severe hypoxaemia from intrapulmonary shunting, pulmonary hypertension due to elevated PVR and areas with a low ventilation/perfusion ratio (<a href="./references#CD007733-bbs2-0069" title="SchusterKM , AlouidorR , BarquistES . Nonventilatory interventions in the acute respiratory distress syndrome. Journal of Intensive Care Medicine2008;23(1):19‐32. [PUBMED: 18230633] ">Schuster 2008</a>). Pulmonary hypertension is believed to be caused by mechanical obstruction of the pulmonary microcirculation by microthromboemboli (composed of platelets and leukocytes) and hypoxic pulmonary vasoconstriction due to alveolar and interstitial oedema triggered by inflammatory mediators (<a href="./references#CD007733-bbs2-0060" title="MoloneyED , EvansTW . Pathophysiology and pharmacological treatment of pulmonary hypertension in acute respiratory distress syndrome. European Respiratory Journal2003;21(4):720‐7. [PUBMED: 12762363] ">Moloney 2003</a>). </p> <p>Although people with ARDS are a heterogeneous population, they are all characterized by having local and systemic inflammation that causes lung damage and fluid leakage across the alveolar‐capillary barrier (<a href="./references#CD007733-bbs2-0062" title="PiantadosiCA , SchwartzDA . The acute respiratory distress syndrome. Annals of Internal Medicine2004;141(6):460‐70. [PUBMED: 15381520] ">Piantadosi 2004</a>). This inflammation can result in multiple organ failure and death. Aerosolized prostacyclins are used because of the potential benefit of modifying the process of inflammation, preserving or restoring oxygen delivery and decreasing mortality in people with ARDS (<a href="./references#CD007733-bbs2-0071" title="SiobalM . Aerosolized prostacyclins. Respiratory Care2004;49(6):640‐52. [PUBMED: 15165299] ">Siobal 2004</a>). Aerosolized prostacyclins are used as an alternative to INO due to various advantages (cost, setup and administration), but this strategy is controversial as the evidence for using prostacyclins is unclear. There are indications of harmful effects of INO in ARDS (<a href="./references#CD007733-bbs2-0033" title="AdhikariNK , BurnsKE , FriedrichJO , GrantonJT , CookDJ , MeadeMO . Effect of nitric oxide on oxygenation and mortality in acute lung injury: systematic review and meta‐analysis. BMJ2007;334(7597):779. [PUBMED: 17383982] ">Adhikari 2007</a>; <a href="./references#CD007733-bbs2-0037" title="BarringtonKJ , FinerNN . Inhaled nitric oxide for respiratory failure in preterm infants. Cochrane Database of Systematic Reviews2007, Issue 3. [DOI: 10.1002/14651858.CD000509.pub3] ">Barrington 2007</a>; <a href="./references#CD007733-bbs2-0048" title="GebistorfF , KaramO , WetterslevJ , AfshariA . Inhaled nitric oxide for acute respiratory distress syndrome (ARDS) in children and adults. Cochrane Database of Systematic Reviews2016, Issue 6. [DOI: 10.1002/14651858.CD002787.pub3] ">Gebistorf 2016</a>). </p> <p>There are no previous systematic reviews on this topic and, being a very costly treatment, the benefit and efficacy of aerosolized prostacyclin in people with ARDS is still controversial and debated. The aim of this updated review was to assess whether aerosolized prostacyclin therapy is beneficial for people with ARDS. </p> <p>All abbreviations are explained in <a href="./appendices#CD007733-sec-0075">Appendix 1</a>. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD007733-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD007733-sec-0014"></div> <p>To assess the benefits and harms of aerosolized prostacyclin in adults and children with ARDS </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD007733-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD007733-sec-0015"></div> <section id="CD007733-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD007733-sec-0017"> <h4 class="title">Types of studies</h4> <p>We included parallel group, RCTs irrespective of publication status, date of publication, blinding status, outcomes published or language. We contacted trial investigators and study authors to ask for relevant data. We included unpublished trials only if trial data and methodological descriptions were provided in written form or could be retrieved from the trial authors. </p> <p>We excluded trials using quasi‐randomization and observational studies.</p> <p>Intravenous prostacyclin and PGE<sub>1</sub> are potent systemic and pulmonary vasodilators that act as potent platelet aggregation inhibitors. They increase the risk of bleeding and adversely affect ventilation to perfusion matching and oxygenation (<a href="./references#CD007733-bbs2-0071" title="SiobalM . Aerosolized prostacyclins. Respiratory Care2004;49(6):640‐52. [PUBMED: 15165299] ">Siobal 2004</a>). Since aerosolized prostacyclins are believed to have more selective properties with little systemic spillover, we chose not to include intravenous trials. </p> </section> <section id="CD007733-sec-0018"> <h4 class="title">Types of participants</h4> <p>We included adults and children defined as having ALI or ARDS according to the various definitions presented in the literature. Despite the 2012 revision of terminology (<a href="./references#CD007733-bbs2-0065" title="ARDS Definition Task Force, RanieriV , RubenfeldG , ThompsonB , FergusonN , CaldwellE , FanE , et al. Acute respiratory distress syndrome: the Berlin Definition. JAMA2012;307(23):2526‐33. [PUBMED: 22797452] ">Ranieri 2012</a>), the previous version of this review aimed to include trials with ALI and ARDS (<a href="./references#CD007733-bbs2-0082" title="AfshariA , BrokJ , MøllerAM , WetterslevJ . Aerosolized prostacyclin for acute lung injury (ALI) and acute respiratory distress syndrome (ARDS). Cochrane Database of Systematic Reviews2010, Issue 8. [DOI: 10.1002/14651858.CD007733; PUBMED: 20687093] ">Afshari 2010</a>). Thus, in case of detection of trials adhering to previous definitions of ARDS and ALI, we did not exclude these trials. We chose to accept the terms standard treatment of ARDS and critically ill people as reported by many authors, despite ongoing controversy. We excluded neonates with 'bronchopulmonary dysplasia' or 'chronic lung disease' due to the different pathophysiology, treatment, prognosis and progression of the disease. </p> </section> <section id="CD007733-sec-0019"> <h4 class="title">Types of interventions</h4> <p>We included trials comparing aerosolized prostacyclins with placebo or no intervention. We chose to include any type or dose of aerosolized prostacyclin for any duration of administration. Any cointervention was allowed if it was administered in both groups. We excluded trials if the only aim was to compare the efficacy of different doses or types of prostacyclins and which did not have a control group without prostacyclin administration. </p> <p>We did not intend to compare aerosolized prostacyclin with INO since, in our view, this comparison justifies the need for a separate systematic review in light of the controversy surrounding the use of INO for ARDS and ALI (<a href="./references#CD007733-bbs2-0033" title="AdhikariNK , BurnsKE , FriedrichJO , GrantonJT , CookDJ , MeadeMO . Effect of nitric oxide on oxygenation and mortality in acute lung injury: systematic review and meta‐analysis. BMJ2007;334(7597):779. [PUBMED: 17383982] ">Adhikari 2007</a>; <a href="./references#CD007733-bbs2-0048" title="GebistorfF , KaramO , WetterslevJ , AfshariA . Inhaled nitric oxide for acute respiratory distress syndrome (ARDS) in children and adults. Cochrane Database of Systematic Reviews2016, Issue 6. [DOI: 10.1002/14651858.CD002787.pub3] ">Gebistorf 2016</a>). Indeed, we did not identify RCTs comparing aerosolized prostacyclin and INO. </p> </section> <section id="CD007733-sec-0020"> <h4 class="title">Types of outcome measures</h4> <section id="CD007733-sec-0021"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD007733-list-0003"> <li> <p>Overall mortality. We used the longest follow‐up data from each trial regardless of the period of follow‐up. </p> </li> <li> <p>Overall 28‐day mortality (data presented at 30 days are to be incorporated in this analysis) </p> </li> </ol> </p> </section> <section id="CD007733-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD007733-list-0004"> <li> <p>Resolution of multiple organ failure (according to different organ dysfunction scores).</p> </li> <li> <p>Bleeding events. We defined bleeding events as pulmonary or systemic bleeding requiring transfusion. We planned to count repeated transfusions in the same participant as a single event. </p> </li> <li> <p>Complications during inpatient stay (e.g. hypotensive episodes, direct irritation on administration, thrombosis, congestive cardiac failure, myocardial infarction, renal failure, cerebrovascular accident). </p> </li> <li> <p>Quality of life assessment, as defined by the authors in the included studies.</p> </li> <li> <p>Duration of mechanical ventilation.</p> </li> <li> <p>Improvement of respiratory failure (ventilator‐free days).</p> </li> <li> <p>Mean pulmonary arterial pressure (MPAP) (mmHg).</p> </li> <li> <p>Partial pressure of oxygen in arterial blood/fraction of inspired oxygen (PaO<sub>2</sub>/FiO<sub>2</sub>) ratio. </p> </li> <li> <p>Oxygenation index defined as [100 × mean airway pressure/(PaO<sub>2</sub>/FiO<sub>2</sub>)] or [(mean airway pressure × FiO<sub>2</sub> × 100)/systemic arterial oxygen tension]. </p> </li> <li> <p>Number of days in hospital.</p> </li> <li> <p>Mean length of stay in an intensive care unit (ICU).</p> </li> <li> <p>Cost‐benefit analyses.</p> </li> </ol> </p> </section> </section> </section> <section id="CD007733-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD007733-sec-0024"> <h4 class="title">Electronic searches</h4> <p>In this updated review, we extended the original review's search from December 2010 (<a href="./references#CD007733-bbs2-0082" title="AfshariA , BrokJ , MøllerAM , WetterslevJ . Aerosolized prostacyclin for acute lung injury (ALI) and acute respiratory distress syndrome (ARDS). Cochrane Database of Systematic Reviews2010, Issue 8. [DOI: 10.1002/14651858.CD007733; PUBMED: 20687093] ">Afshari 2010</a>). Thus, we searched the Cochrane Central Register of Controlled Trials (CENTRAL; 2017, Issue 4). We updated our search of MEDLINE (OvidSP, to 5 May 2017), Embase (OvidSP, to 5 May 2017), CINAHL (EBSCOhost; to 5 May 2017), ISI Web of Science (to 5 May 2017), ISI BIOSIS Previews (to 5 May 2017) and Latin American Caribbean Health Sciences Literature (LILACS; via BIREME) (to 5 May 2017). The search is now from inception to 5 May 2017. For specific information regarding our search strategies and results, see <a href="./appendices#CD007733-sec-0076">Appendix 2</a>. </p> <p>We imposed no language restrictions.</p> </section> <section id="CD007733-sec-0025"> <h4 class="title">Searching other resources</h4> <p>We searched for ongoing clinical trials and unpublished trials on the following Internet sites: </p> <p> <ol id="CD007733-list-0005"> <li> <p>ISRCTN registry (<a href="http://www.controlled-trials.com" target="_blank">www.controlled‐trials.com</a>); </p> </li> <li> <p>ClinicalTrials.gov (<a href="http://clinicaltrials.gov" target="_blank">clinicaltrials.gov</a>); </p> </li> <li> <p>CenterWatch (<a href="http://www.centerwatch.com" target="_blank">www.centerwatch.com</a>). </p> </li> </ol> </p> <p>We handsearched the reference lists of reviews, randomized and non‐randomized trials, and editorials for additional trials. We contacted the main authors of trials in this field to ask for any missed, unreported or ongoing studies. </p> <p>We applied no language restrictions to eligible reports. We conducted the latest search on 5 May 2017. </p> </section> </section> <section id="CD007733-sec-0026"> <h3 class="title" id="CD007733-sec-0026">Data collection and analysis</h3> <p>Two review authors (MA, ABB) independently screened and classified all citations as potential primary studies, review articles or other. The two review authors also independently examined all potential primary studies and decided on their inclusion in the review. We independently abstracted and evaluated methodology and outcomes from each trial, in accordance with the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD007733-bbs2-0051" title="HigginsJPT , GreenS . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). We resolved disagreements by consensus among the review authors. </p> <section id="CD007733-sec-0027"> <h4 class="title">Selection of studies</h4> <p>We assessed the reports identified from the described searches and excluded obviously irrelevant reports. We screened all articles by title and abstract, and then as full‐text articles for inclusion. We listed all excluded studies with reasons for their exclusion in the <a href="./references#CD007733-sec-0098" title="">Characteristics of excluded studies</a> table. </p> <p>Two review authors (MA, ABB) independently examined the retrieved reports for eligibility. We performed this process without blinding to study authors, institution, journal of publication or results. We resolved disagreements by consensus among the review authors. We provide a detailed description of the search and assessment (<a href="./appendices#CD007733-sec-0076">Appendix 2</a>). </p> </section> <section id="CD007733-sec-0028"> <h4 class="title">Data extraction and management</h4> <p>We independently extracted and collected data from each trial without blinding to study authors, source institutions or publication source of trials. We resolved disagreements by discussion and approached all first authors of included trials for additional information on risks of bias. For more detailed information, see <a href="#CD007733-sec-0087">Contributions of authors</a>. </p> </section> <section id="CD007733-sec-0029"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We evaluated the validity and design characteristics of each trial.</p> <p>We evaluated trials for major potential sources of bias (random sequence generation, allocation concealment, blinding of participants, blinding of personnel, blinding of primary outcome assessor, blinding of secondary outcome assessor, incomplete outcome data, selective reporting and other bias; see <a href="./appendices#CD007733-sec-0077">Appendix 3</a>). We assessed each trial quality factor separately and defined trials as having low risk of bias only if they adequately fulfilled all the criteria described in <a href="./appendices#CD007733-sec-0077">Appendix 3</a> and in accordance with the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD007733-bbs2-0051" title="HigginsJPT , GreenS . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). </p> </section> <section id="CD007733-sec-0030"> <h4 class="title">Measures of treatment effect</h4> <section id="CD007733-sec-0031"> <h5 class="title">Dichotomous data</h5> <p>We calculated risk ratios (RRs) with 95% confidence intervals (CIs) for dichotomous data (binary outcomes). These included the following: </p> <section id="CD007733-sec-0032"> <h6 class="title">Primary outcome</h6> <p> <ol id="CD007733-list-0006"> <li> <p>Overall mortality.</p> </li> </ol> </p> </section> <section id="CD007733-sec-0033"> <h6 class="title">Secondary outcomes</h6> <p> <ol id="CD007733-list-0007"> <li> <p>Resolution of multiple organ failure;</p> </li> <li> <p>Bleeding events;</p> </li> <li> <p>Complications during inpatient stay.</p> </li> </ol> </p> </section> </section> <section id="CD007733-sec-0034"> <h5 class="title">Continuous data</h5> <p>We used the mean difference (MD) if data were continuous and were measured in the same way between trials as follows: </p> <section id="CD007733-sec-0035"> <h6 class="title">Secondary outcomes</h6> <p> <ol id="CD007733-list-0008"> <li> <p>Quality of life assessment</p> </li> <li> <p>Duration of mechanical ventilation</p> </li> <li> <p>Improvement of respiratory failure (ventilator‐free days).</p> </li> <li> <p>Mean pulmonary arterial pressure (MPAP) (mmHg).</p> </li> <li> <p>PaO<sub>2</sub>/FiO<sub>2</sub> ratio. </p> </li> <li> <p>Oxygenation index defined as [100 × mean airway pressure/(PaO<sub>2</sub>/FiO<sub>2</sub>)] or [(mean airway pressure × FiO<sub>2</sub> × 100)/systemic arterial oxygen tension]. </p> </li> <li> <p>Number of days in hospital.</p> </li> <li> <p>Mean length of stay in an intensive care unit (ICU).</p> </li> <li> <p>Cost benefit analyses</p> </li> </ol> </p> </section> </section> </section> <section id="CD007733-sec-0036"> <h4 class="title">Unit of analysis issues</h4> <section id="CD007733-sec-0037"> <h5 class="title">Cross‐over trials</h5> <p>We planned to exclude cross‐over trials from meta‐analyses because of the potential risk for 'carry‐over' of intervention effect. However, if considered important, these trials were to be included only in a descriptive manner in this review due to the lack of evidence. </p> </section> <section id="CD007733-sec-0038"> <h5 class="title">Studies with multiple intervention groups</h5> <p>In studies designed with multiple intervention groups, we planned to combine groups to create a single pair‐wise comparison in accordance with the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD007733-bbs2-0051" title="HigginsJPT , GreenS . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). In trials with two or more groups receiving different doses, we aimed to combine data for primary and secondary outcomes. </p> </section> </section> <section id="CD007733-sec-0039"> <h4 class="title">Dealing with missing data</h4> <p>We contacted the authors of trials with missing data to retrieve the relevant information. For all included studies, we noted levels of attrition and any exclusions. In case of missing data, we chose 'complete‐case analysis' for our primary outcomes, which excludes from the analysis all participants with the outcome missing. Selective outcome reporting occurs when non‐significant results are selectively withheld from publication (<a href="./references#CD007733-bbs2-0040" title="ChanAW , HróbjartssonA , HaahrMT , GøtzschePC , AltmanDG . Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles. JAMA2004;291(20):2457‐65. [PUBMED: 15161896] ">Chan 2004</a>), and is defined as the selection, on the basis of the results, of a subset of the original variables recorded for inclusion in publication of trials (<a href="./references#CD007733-bbs2-0053" title="HuttonJL , WilliamsonPR . Bias in meta‐analysis due to outcome variable selection within studies. Journal of the Royal Statistical Society. Series C, Applied Statistics2000;49(3):359‐70. [DOI: 10.1111/1467‐9876.00197] ">Hutton 2000</a>). The most important types of selective outcome reporting are: selective omission of outcomes from reports; selective choice of data for an outcome; selective reporting of different analyses using the same data; selective reporting of subsets of the data and selective under‐reporting of data (<a href="./references#CD007733-bbs2-0051" title="HigginsJPT , GreenS . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). </p> </section> <section id="CD007733-sec-0040"> <h4 class="title">Assessment of reporting biases</h4> <p><b>Publication bias</b> occurs when the publication of research results depends on their nature and direction (<a href="./references#CD007733-bbs2-0043" title="DickersinK . The existence of publication bias and risk factors for its occurrence. JAMA1990;263(10):1385‐9. [PUBMED: 2406472] ">Dickersin 1990</a>). We planned to provide a funnel plot to detect either publication bias or a difference between smaller and larger studies ('small‐study effects') expressed by asymmetry (<a href="./references#CD007733-bbs2-0044" title="EggerM , Davey SmithG , SchneiderM , MinderC . Bias in metaanalysis detected by a simple, graphical test. BMJ1997;315(7109):629‐34. [PUBMED: 9310563] ">Egger 1997</a>). To quantify this asymmetry in meta‐analyses with binary outcomes, we also intended to apply the arcsine test as proposed by <a href="./references#CD007733-bbs2-0068" title="RückerG , SchwarzerG , CarpenterJ . Arcsine test for publication bias in meta‐analyses with binary outcomes. Statistics in Medicine2008;27(5):746‐63. [PUBMED: 17592831] ">Rücker 2008</a>. This test has the advantage of including trials with no events. </p> <p>According to the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> a minimum of 10 trials has to be included before a statistical test is applied, to detect possible reporting bias, and results from tests for funnel plot asymmetry should be interpreted cautiously (<a href="./references#CD007733-bbs2-0051" title="HigginsJPT , GreenS . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). </p> </section> <section id="CD007733-sec-0041"> <h4 class="title">Data synthesis</h4> <section id="CD007733-sec-0042"> <h5 class="title">Data analysis</h5> <p>We used Review Manager 5 software (<a href="./references#CD007733-bbs2-0066" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>) and calculated MDs with 95% CIs for continuous outcomes and RRs with 95% CIs for dichotomous variables. We used the Chi<sup>2</sup> test to obtain an indication of heterogeneity between studies, with P value ≤ 0.1 considered significant. We quantified the degree of heterogeneity observed in the results by using the I<sup>2</sup> statistic, which can be interpreted as the proportion of total variation observed between studies that is attributable to differences between studies rather than to sampling error (<a href="./references#CD007733-bbs2-0051" title="HigginsJPT , GreenS . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). An I<sup>2</sup> statistic greater than 75% is considered as very heterogeneous. Suggested threshold values for the I<sup>2</sup> statistic are: low (25% to 49%), moderate (50% to 74%) and high (75% or greater) (<a href="./references#CD007733-bbs2-0050" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327(7414):557‐60. [PUBMED: 12958120] ">Higgins 2003</a>). If I<sup>2</sup> = 0, we planned to report only the results from the fixed‐effect model; in the case of an I<sup>2</sup> greater than 0, we planned to report only the results from the random‐effects model unless one or two trials comprised more than 60% (weight %) of the total evidence provided, in which case the random‐effects model may be biased. The latter is to make the review more readable. We believe that there is little value in using a fixed‐effect model in cases of substantial heterogeneity possibly due to the various reasons leading to ARDS (clinical heterogeneity). Additionally, in the case of an I<sup>2</sup> greater than 0 (mortality outcome), we planned to determine the cause of heterogeneity by performing relevant subgroup analyses. We intended to pool trial results only in the case of low clinical heterogeneity. </p> </section> <section id="CD007733-sec-0043"> <h5 class="title">Trial sequential analysis</h5> <p>Risk of type 1 errors in meta‐analyses due to sparse data and repeated significance testing following updates with new trials remains a serious concern (<a href="./references#CD007733-bbs2-0039" title="BrokJ , ThorlundK , WetterslevJ , GluudC . Apparently conclusive meta‐analyses may be inconclusive ‐ trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta‐analyses. Journal of Clinical Epidemiology2009;38(1):287‐98. [PUBMED: 18824466] ">Brok 2009</a>; <a href="./references#CD007733-bbs2-0073" title="ThorlundK , DevereauxPJ , WetterslevJ , GuyattG , IoannidisJP , ThabaneL , et al. Can trial sequential monitoring boundaries reduce spurious inferences from meta‐analyses?. International Journal of Epidemiology2009;38(1):276‐86. [PUBMED: 18824467] ">Thorlund 2009</a>; <a href="./references#CD007733-bbs2-0077" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Trial sequential analysis may establish when firm evidence is reached in cumulative meta‐analysis. Journal of Clinical Epidemiology2008;61(1):64‐75. [PUBMED: 18083463] ">Wetterslev 2008</a>; <a href="./references#CD007733-bbs2-0078" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Estimating required information size by quantifying diversity in random‐effects model meta‐analyses. BMC Medical Research Methodology2009;9:86. [PUBMED: 20042080] ">Wetterslev 2009</a>). As a result, spurious P values due to systematic errors from trials with high risk of bias, outcome reporting bias, publication bias, early stopping for benefit and small‐study bias may result in false conclusions. In a single trial, interim analysis increases the risk of type 1 errors. To avoid type 1 errors, group sequential monitoring boundaries (<a href="./references#CD007733-bbs2-0056" title="LanKKG , DeMetsDL . Discrete sequential boundaries for clinical trials. Biometrika1983;70:659‐63. [uame‐roche.com/public/web/images/bibliografia/discrete_sequential_boundaries.pdf] ">Lan 1983</a>) are used to decide whether a trial could be terminated early because of a sufficiently small P value, thus the cumulative Z curve crosses the monitoring boundary. </p> <p>Equally, sequential monitoring boundaries can be applied to meta‐analyses and are labelled 'trial sequential monitoring boundaries.' In 'trial sequential analysis' (TSA) (<a href="./references#CD007733-bbs2-0074" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Trial Sequential Analysis, version 0.8. Copenhagen: Copenhagen Trial Unit, 2010. ">TSA 2010</a>), the addition of each new trial to a cumulative meta‐analysis is viewed as an interim meta‐analysis, which provides useful information on the need for additional trials (<a href="./references#CD007733-bbs2-0077" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Trial sequential analysis may establish when firm evidence is reached in cumulative meta‐analysis. Journal of Clinical Epidemiology2008;61(1):64‐75. [PUBMED: 18083463] ">Wetterslev 2008</a>). </p> <p>It is appropriate and wise to adjust new meta‐analyses for multiple testing on accumulating data to control overall type 1 error risk in cumulative meta‐analysis (<a href="./references#CD007733-bbs2-0063" title="PogueJM , YusufS . Cumulating evidence from randomized trials: utilizing sequential monitoring boundaries for cumulative meta‐analysis. Controlled Clinical Trials1997;18(6):580‐93. [PUBMED: 9408720] ">Pogue 1997</a>; <a href="./references#CD007733-bbs2-0064" title="PogueJ , YusufS . Overcoming the limitations of current meta‐analysis of randomized controlled trials. Lancet1998;351(9095):45‐52. [PUBMED: 9433436] ">Pogue 1998</a>; <a href="./references#CD007733-bbs2-0073" title="ThorlundK , DevereauxPJ , WetterslevJ , GuyattG , IoannidisJP , ThabaneL , et al. Can trial sequential monitoring boundaries reduce spurious inferences from meta‐analyses?. International Journal of Epidemiology2009;38(1):276‐86. [PUBMED: 18824467] ">Thorlund 2009</a>; <a href="./references#CD007733-bbs2-0077" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Trial sequential analysis may establish when firm evidence is reached in cumulative meta‐analysis. Journal of Clinical Epidemiology2008;61(1):64‐75. [PUBMED: 18083463] ">Wetterslev 2008</a>). </p> <p>When TSA is performed, the cumulative Z curve crossing the boundary indicates that a sufficient level of evidence has been reached; as a consequence, one may conclude that no additional trials may be needed. However, evidence is insufficient to allow a conclusion if the Z curve does not cross the boundary or does not surpass the required information size. </p> <p>To construct trial sequential monitoring boundaries, one needs a required information size, which is calculated as the least number of participants required in a well‐powered single trial with low risk of bias (<a href="./references#CD007733-bbs2-0039" title="BrokJ , ThorlundK , WetterslevJ , GluudC . Apparently conclusive meta‐analyses may be inconclusive ‐ trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta‐analyses. Journal of Clinical Epidemiology2009;38(1):287‐98. [PUBMED: 18824466] ">Brok 2009</a>; <a href="./references#CD007733-bbs2-0064" title="PogueJ , YusufS . Overcoming the limitations of current meta‐analysis of randomized controlled trials. Lancet1998;351(9095):45‐52. [PUBMED: 9433436] ">Pogue 1998</a>; <a href="./references#CD007733-bbs2-0077" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Trial sequential analysis may establish when firm evidence is reached in cumulative meta‐analysis. Journal of Clinical Epidemiology2008;61(1):64‐75. [PUBMED: 18083463] ">Wetterslev 2008</a>). </p> <p>In this updated review, we planned to adjust the required information size for heterogeneity by using the diversity adjustment factor (<a href="./references#CD007733-bbs2-0078" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Estimating required information size by quantifying diversity in random‐effects model meta‐analyses. BMC Medical Research Methodology2009;9:86. [PUBMED: 20042080] ">Wetterslev 2009</a>). We aimed to apply TSA, as it prevents an increase in the risk of type 1 errors (20%). If the actual accrued information size was considered too small, we planned to provide the required information size in the light of actual diversity (<a href="./references#CD007733-bbs2-0078" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Estimating required information size by quantifying diversity in random‐effects model meta‐analyses. BMC Medical Research Methodology2009;9:86. [PUBMED: 20042080] ">Wetterslev 2009</a>). </p> </section> </section> <section id="CD007733-sec-0044"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned the following subgroup analyses.</p> <p> <ol id="CD007733-list-0009"> <li> <p>Assessment of the benefits and harms of prostacyclins in participants with ARDS based on the cause (primary lung injury versus secondary lung injury). </p> </li> <li> <p>Assessment of the benefits and harms of prostacyclins in children (paediatric, age less than 18 years) versus adults. </p> </li> <li> <p>Assessment of the benefits and harms of prostacyclins based on the duration of drug administration. </p> </li> </ol> </p> <p>If analyses of various subgroups were significant, we planned to perform a test of interaction (<a href="./references#CD007733-bbs2-0034" title="AltmanDG , BlandJM . Interaction revisited: the difference between two estimates. BMJ2003;326(7382):219. [PUBMED: 12543843] ">Altman 2003</a>). We considered P &lt; 0.05 as indicating significant interaction between the prostacyclin effect on mortality and subgroup category (<a href="./references#CD007733-bbs2-0051" title="HigginsJPT , GreenS . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). </p> </section> <section id="CD007733-sec-0045"> <h4 class="title">Sensitivity analysis</h4> <p>We planned the following sensitivity analyses for the primary outcomes.</p> <p> <ol id="CD007733-list-0010"> <li> <p>Comparing estimates of the pooled intervention effect in trials with low risk of bias to estimates from trials with high risk of bias (i.e. trials having at least one inadequate risk of bias component). </p> </li> <li> <p>Comparing estimates of the pooled intervention effect in trials based on different components of risk of bias (random sequence generation, allocation concealment, blinding, follow‐up, intention to treat (ITT)). </p> </li> <li> <p>Comparing estimates of the pooled intervention effect in trials based on The ARDS Definition Task Force (<a href="./references#CD007733-bbs2-0065" title="ARDS Definition Task Force, RanieriV , RubenfeldG , ThompsonB , FergusonN , CaldwellE , FanE , et al. Acute respiratory distress syndrome: the Berlin Definition. JAMA2012;307(23):2526‐33. [PUBMED: 22797452] ">Ranieri 2012</a>). </p> </li> <li> <p>Assessment of the benefits and harms of prostacyclins in participants with ARDS versus participants given placebo or usual care when excluding data from studies only published as abstracts. </p> </li> <li> <p>Assessment of the benefits and harms of aerosolized prostacyclin in participants with ARDS versus participants given placebo or usual care when excluding trials with zero events. </p> </li> <li> <p>Examining the role of funding bias when excluding trials that were exclusively sponsored by pharmaceutical companies. </p> </li> </ol> </p> <p>We planned to calculate RR with 95% CI and apply complete case analysis, if possible, for our sensitivity and subgroup analyses based on our primary outcome measure (mortality). </p> <section id="CD007733-sec-0046"> <h5 class="title">'Summary of findings' table and GRADE</h5> <p>We used the principles of the GRADE approach to provide an overall assessment of evidence related to all our outcomes. We constructed <a href="./full#CD007733-tbl-0001">summary of findings Table for the main comparison</a> using GRADEpro software (<a href="./references#CD007733-bbs2-0049" title="GRADE Working Group, McMaster University. GRADEpro GDT. Hamilton (ON): GRADE Working Group, McMaster University, 2015. ">GRADEpro</a>). However, one may argue the true value of this table based on the limited number of RCTs and the quality of published data and their design limitations. As outcomes of public interest, we presented overall mortality (regardless of the follow‐up period), PaO<sub>2</sub>/FiO<sub>2</sub> ratio and adverse events (see <a href="./full#CD007733-tbl-0001">summary of findings Table for the main comparison</a>). </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD007733-sec-0047" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD007733-sec-0047"></div> <section id="CD007733-sec-0048"> <h3 class="title">Description of studies</h3> <section id="CD007733-sec-0049"> <h4 class="title">Results of the search</h4> <p>Through electronic searches and from references of potentially relevant articles, we identified 3563 publications. We excluded 3517 publications as they were either duplicates or were clearly irrelevant (<a href="#CD007733-fig-0001">Figure 1</a>). A total of 46 potentially relevant publications were retrieved for further assessment. From these, we excluded 43 trials. The previous review classified two trials as ongoing (<a href="./references#CD007733-bbs2-0082" title="AfshariA , BrokJ , MøllerAM , WetterslevJ . Aerosolized prostacyclin for acute lung injury (ALI) and acute respiratory distress syndrome (ARDS). Cochrane Database of Systematic Reviews2010, Issue 8. [DOI: 10.1002/14651858.CD007733; PUBMED: 20687093] ">Afshari 2010</a>). One of them was terminated prior to enrolment (<a href="./references#CD007733-bbs2-0016" title="NCT00981591 . Inhaled iloprost as an adjunct to inhaled nitric oxide in pediatric critical care patients. clinicaltrials.gov/ct2/show/NCT00981591 Date first received: 18 September 2009. ">NCT00981591</a>), and therefore excluded. The other was completed and included (<a href="./references#CD007733-bbs2-0002" title="SiddiquiS , SalahuddinN , ZubairS , YousufM , AzamI , GilaniAH . Use of inhaled PGE1 to improve diastolic dysfunction, LVEDP, pulmonary hypertension and hypoxia in ARDS ‐ a randomised clinical trial. Open Journal of Anesthesiology2013;3(2):109‐15. [DOI: 10.4236/ojanes.2013.32027] ">Siddiqui 2013</a>). We have now included two trials with 81 participants (<a href="./references#CD007733-bbs2-0001" title="DahlemP , vanAalderenWM , deNeefM , DijkgraafMG , BosAP . Randomized controlled trial of aerosolized prostacyclin therapy in children with acute lung injury. Critical Care Medicine2004;32(4):1055‐60. [PUBMED: 15071401] ">Dahlem 2004</a>; <a href="./references#CD007733-bbs2-0002" title="SiddiquiS , SalahuddinN , ZubairS , YousufM , AzamI , GilaniAH . Use of inhaled PGE1 to improve diastolic dysfunction, LVEDP, pulmonary hypertension and hypoxia in ARDS ‐ a randomised clinical trial. Open Journal of Anesthesiology2013;3(2):109‐15. [DOI: 10.4236/ojanes.2013.32027] ">Siddiqui 2013</a>). The three review authors (MA, ABB and AA) completely agreed on the selection of the included studies. We obtained additional information from the lead authors of both trials. </p> <div class="figure" id="CD007733-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD007733-fig-0001" src="/cdsr/doi/10.1002/14651858.CD007733.pub3/media/CDSR/CD007733/image_n/nCD007733-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD007733-sec-0050"> <h4 class="title">Included studies</h4> <p>Only two trials met the entry criteria for this systematic review (<a href="./references#CD007733-bbs2-0001" title="DahlemP , vanAalderenWM , deNeefM , DijkgraafMG , BosAP . Randomized controlled trial of aerosolized prostacyclin therapy in children with acute lung injury. Critical Care Medicine2004;32(4):1055‐60. [PUBMED: 15071401] ">Dahlem 2004</a>; <a href="./references#CD007733-bbs2-0002" title="SiddiquiS , SalahuddinN , ZubairS , YousufM , AzamI , GilaniAH . Use of inhaled PGE1 to improve diastolic dysfunction, LVEDP, pulmonary hypertension and hypoxia in ARDS ‐ a randomised clinical trial. Open Journal of Anesthesiology2013;3(2):109‐15. [DOI: 10.4236/ojanes.2013.32027] ">Siddiqui 2013</a>). Both trials were carried out at a single centre, one in the Netherlands and one in Pakistan. The details of the included studies are provided in the <a href="./references#CD007733-sec-0097" title="">Characteristics of included studies</a> table. One trial included only children (<a href="./references#CD007733-bbs2-0001" title="DahlemP , vanAalderenWM , deNeefM , DijkgraafMG , BosAP . Randomized controlled trial of aerosolized prostacyclin therapy in children with acute lung injury. Critical Care Medicine2004;32(4):1055‐60. [PUBMED: 15071401] ">Dahlem 2004</a>), and one trial included only adults aged 18 years or over (<a href="./references#CD007733-bbs2-0002" title="SiddiquiS , SalahuddinN , ZubairS , YousufM , AzamI , GilaniAH . Use of inhaled PGE1 to improve diastolic dysfunction, LVEDP, pulmonary hypertension and hypoxia in ARDS ‐ a randomised clinical trial. Open Journal of Anesthesiology2013;3(2):109‐15. [DOI: 10.4236/ojanes.2013.32027] ">Siddiqui 2013</a>). The two included trials involved 81 participants. </p> <p><a href="./references#CD007733-bbs2-0001" title="DahlemP , vanAalderenWM , deNeefM , DijkgraafMG , BosAP . Randomized controlled trial of aerosolized prostacyclin therapy in children with acute lung injury. Critical Care Medicine2004;32(4):1055‐60. [PUBMED: 15071401] ">Dahlem 2004</a> had a cross‐over design; two groups of participants: one group initially treated with aerosolized prostacyclin followed by normal saline and the other group initially treated with normal saline followed by aerosolized prostacyclin . Due to the cross‐over design, mortality results therefore merely referred to the effect of the sequence of drug administration rather than potential benefits or harms of the drug per se. </p> <p><a href="./references#CD007733-bbs2-0002" title="SiddiquiS , SalahuddinN , ZubairS , YousufM , AzamI , GilaniAH . Use of inhaled PGE1 to improve diastolic dysfunction, LVEDP, pulmonary hypertension and hypoxia in ARDS ‐ a randomised clinical trial. Open Journal of Anesthesiology2013;3(2):109‐15. [DOI: 10.4236/ojanes.2013.32027] ">Siddiqui 2013</a> used PGE<sub>1</sub> (alprostadil) 20 μg as intervention and normal saline as control; both dispensed in 5 mL of saline nebulized continuously over 30 minutes. </p> <p>The duration of intervention was less than 24 hours in both trials (<a href="./references#CD007733-bbs2-0001" title="DahlemP , vanAalderenWM , deNeefM , DijkgraafMG , BosAP . Randomized controlled trial of aerosolized prostacyclin therapy in children with acute lung injury. Critical Care Medicine2004;32(4):1055‐60. [PUBMED: 15071401] ">Dahlem 2004</a>; <a href="./references#CD007733-bbs2-0002" title="SiddiquiS , SalahuddinN , ZubairS , YousufM , AzamI , GilaniAH . Use of inhaled PGE1 to improve diastolic dysfunction, LVEDP, pulmonary hypertension and hypoxia in ARDS ‐ a randomised clinical trial. Open Journal of Anesthesiology2013;3(2):109‐15. [DOI: 10.4236/ojanes.2013.32027] ">Siddiqui 2013</a>). Length of follow‐up was 28 days in <a href="./references#CD007733-bbs2-0001" title="DahlemP , vanAalderenWM , deNeefM , DijkgraafMG , BosAP . Randomized controlled trial of aerosolized prostacyclin therapy in children with acute lung injury. Critical Care Medicine2004;32(4):1055‐60. [PUBMED: 15071401] ">Dahlem 2004</a> and not stated in <a href="./references#CD007733-bbs2-0002" title="SiddiquiS , SalahuddinN , ZubairS , YousufM , AzamI , GilaniAH . Use of inhaled PGE1 to improve diastolic dysfunction, LVEDP, pulmonary hypertension and hypoxia in ARDS ‐ a randomised clinical trial. Open Journal of Anesthesiology2013;3(2):109‐15. [DOI: 10.4236/ojanes.2013.32027] ">Siddiqui 2013</a>. No other cointervention was applied besides standard critical care treatment in both trials (<a href="./references#CD007733-bbs2-0001" title="DahlemP , vanAalderenWM , deNeefM , DijkgraafMG , BosAP . Randomized controlled trial of aerosolized prostacyclin therapy in children with acute lung injury. Critical Care Medicine2004;32(4):1055‐60. [PUBMED: 15071401] ">Dahlem 2004</a>; <a href="./references#CD007733-bbs2-0002" title="SiddiquiS , SalahuddinN , ZubairS , YousufM , AzamI , GilaniAH . Use of inhaled PGE1 to improve diastolic dysfunction, LVEDP, pulmonary hypertension and hypoxia in ARDS ‐ a randomised clinical trial. Open Journal of Anesthesiology2013;3(2):109‐15. [DOI: 10.4236/ojanes.2013.32027] ">Siddiqui 2013</a>). There was no predefined protocol for mechanical ventilation in either trial. As described previously, we chose to include <a href="./references#CD007733-bbs2-0001" title="DahlemP , vanAalderenWM , deNeefM , DijkgraafMG , BosAP . Randomized controlled trial of aerosolized prostacyclin therapy in children with acute lung injury. Critical Care Medicine2004;32(4):1055‐60. [PUBMED: 15071401] ">Dahlem 2004</a> in a descriptive manner since this trial also was included in the previous version of this review but was not considered eligible for meta‐analyses due to the cross‐over design. </p> </section> <section id="CD007733-sec-0051"> <h4 class="title">Excluded studies</h4> <p>We excluded 27 publications (<a href="./references#CD007733-bbs2-0003" title="AbrahamE , ParkYC , CovingtonP , ConradSA , SchwartzM . Liposomal prostaglandin E1 in acute respiratory distress syndrome: a placebo‐controlled, randomized, double‐blind, multicenter clinical trial. Critical Care Medicine1996;24(1):10‐5. [PUBMED: 8565513] ">Abraham 1996</a>; <a href="./references#CD007733-bbs2-0004" title="AbrahamE , BaughmanR , FletcherE , HeardS , LambertiJ , LevyHN , et al. Liposomal prostaglandin E1 (TLC C‐53) in acute respiratory distress syndrome: a controlled, randomized, double‐blind, multicenter clinical trial. TLC C‐53 ARDS Study Group. Critical Care Medicine1999;27(8):1478‐85. [PUBMED: 10470753 ] ">Abraham 1999</a>; <a href="./references#CD007733-bbs2-0006" title="ArcherSL , MikeD , CrowJ , LongW , WeirEK . A placebo‐controlled trial of prostacyclin in acute respiratory failure in COPD. Chest1996;109(3):750‐5. [PUBMED: 8617086] ">Archer 1996</a>; <a href="./references#CD007733-bbs2-0007" title="BeinT , PfeiferM , RieggerGA , TaegerK . Continuous intraarterial measurement of oxygenation during aerosolized prostacyclin administration in severe respiratory failure. New England Journal of Medicine1994;331(5):335‐6. [PUBMED: 8022461] ">Bein 1994</a>; <a href="./references#CD007733-bbs2-0008" title="BoeckL , TammM , GrendelmeierP , StolzD . Acute effects of aerosolized iloprost in COPD related pulmonary hypertension ‐ a randomized controlled crossover trial. PloS One2012;7(12):e52248. [PUBMED: 23300624 ] ">Boeck 2012</a>; <a href="./references#CD007733-bbs2-0009" title="BoneRC , SlotmanG , MaunderR , SilvermanH , HyersTM , KersteinMD , et al. Randomized double‐blind, multicenter study of prostaglandin E1 in patients with the adult respiratory distress syndrome. Prostaglandin E1 Study Group. Chest1989;96(1):114‐9. [PUBMED: 2661155] SilvermanHJ , SlotmanG , BoneRC , MaunderR , HyersTM , KersteinMD , et al. Effects of prostaglandin E1 on oxygen delivery and consumption in patients with the adult respiratory distress syndrome. Results from the prostaglandin E1 multicenter trial. The Prostaglandin E1 Study Group. Chest1990;98(2):405‐10. [PUBMED: 2198140] SlotmanGJ , KersteinMD , BoneRC , SilvermanH , MaunderR , HyersTM , et al. The effects of prostaglandin E1 on non‐pulmonary organ function during clinical acute respiratory failure. The Prostaglandin E1 Study Group. Journal of Trauma1992;32(4):480‐8. [PUBMED: 1569622] ">Bone 1989</a>; <a href="./references#CD007733-bbs2-0010" title="DomenighettiG , StrickerH , WaldispuehlB . Nebulized prostacyclin (PGI2) in acute respiratory distress syndrome: impact of primary (pulmonary injury) and secondary (extrapulmonary injury) disease on gas exchange response. Critical Care Medicine2001;29(1):57‐62. [PUBMED: 11176161] ">Domenighetti 2001</a>; <a href="./references#CD007733-bbs2-0011" title="DunkleyKA , LouzonPR , LeeJ , VuS . Efficacy, safety, and medication errors associated with the use of inhaled epoprostenol for adults with acute respiratory distress syndrome: a pilot study. Annals of Pharmacotherapy2013;47(6):790‐6. [PUBMED: 23656748 ] ">Dunkley 2013</a>; <a href="./references#CD007733-bbs2-0012" title="EichelbrönnerO , ReineltH , WiedeckH , MezödyM , RossaintR , GeorgieffM , et al. Aerosolized prostacyclin and inhaled nitric oxide in septic shock ‐ different effects on splanchnic oxygenation?. Intensive Care Medicine1996;22(9):880‐7. [PUBMED: 8905421] ">Eichelbrönner 1996</a>; <a href="./references#CD007733-bbs2-0013" title="HolcroftJW , VassarMJ , WeberCJ . Prostaglandin E(1) and survival in patients with the adult respiratory distress syndrome: a prospective trial. Seminars in Respiratory Medicine1986;8 Suppl:40‐7. HolcroftJW , VassarMJ , WeberCJ . Prostaglandin E1 and survival in patients with the adult respiratory distress syndrome. A prospective trial. Annals of Surgery1986;203(4):371‐8. [PUBMED: 3516085] ">Holcroft 1986</a>; <a href="./references#CD007733-bbs2-0014" title="LiuD , LuoG , LuoC , WangT , SunG , HeiZ . Changes in the concentrations of mediators of inflammation and oxidative stress in exhaled breath condensate during liver transplantation and their relations with postoperative ARDS. Respiratory Care2015;60(5):679‐88. [PUBMED: 25628453 ] ">Liu 2015</a>; <a href="./references#CD007733-bbs2-0015" title="MeyerJ , TheilmeierG , VanAkenH , BoneHG , BusseH , WaurickR , et al. Inhaled prostaglandin E1 for treatment of acute lung injury in severe multiple organ failure. Anesthesia and Analgesia1998;86(4):753‐8. [PUBMED: 9539597] ">Meyer 1998</a>; <a href="./references#CD007733-bbs2-0016" title="NCT00981591 . Inhaled iloprost as an adjunct to inhaled nitric oxide in pediatric critical care patients. clinicaltrials.gov/ct2/show/NCT00981591 Date first received: 18 September 2009. ">NCT00981591</a>; <a href="./references#CD007733-bbs2-0017" title="PappertD , BuschT , GerlachH , LewandowskiK , RadermacherP , RossaintR . Aerosolized prostacyclin versus inhaled nitric oxide in children with severe acute respiratory distress syndrome. Anesthesiology1995;82(6):1507‐11. [PUBMED: 7793662] ">Pappert 1995</a>; <a href="./references#CD007733-bbs2-0018" title="PutensenC , HörmannC , KleinsasserA , Putensen‐HimmerG . Cardiopulmonary effects of aerosolized prostaglandin E1 and nitric oxide inhalation in patients with acute respiratory distress syndrome. American Journal of Respiratory and Critical Care Medicine1998;157(6 Pt 1):1743‐7. [PUBMED: 9620900] ">Putensen 1998</a>; <a href="./references#CD007733-bbs2-0019" title="RossignonMD , KhayatD , RoyerC , RoubyJJ , JacquillatC , ViarsP . Functional and metabolic activity of polymorphonuclear leukocytes from patients with adult respiratory distress syndrome: results of a randomized double‐blind placebo‐controlled study on the activity of prostaglandin E1. Anesthesiology1990;72(2):276‐81. [PUBMED: 2405741] ">Rossignon 1990</a>; <a href="./references#CD007733-bbs2-0020" title="SawhenyE , EllisAL , KinasewitzGT . Iloprost improves gas exchange in patients with pulmonary hypertension and ARDS. Chest2013;144(1):55‐62. [PUBMED: 23370599] ">Sawheny 2013</a>; <a href="./references#CD007733-bbs2-0021" title="ShoemakerWC , AppelPL . Effects of prostaglandin E1 in adult respiratory distress syndrome. Surgery1986;99(3):275‐83. [PUBMED: 3513357] ">Shoemaker 1986</a>; <a href="./references#CD007733-bbs2-0022" title="SoodB , KeszlerM , GargM , KleinJM , OhlsR , AmbalavananN , et al. Inhaled PGE1 in neonates with hypoxemic respiratory failure: two pilot feasibility randomized clinical trials. Trials2014;15:486. [PUBMED: 25496504] ">Sood 2014</a>; <a href="./references#CD007733-bbs2-0023" title="TorbicH , SzumitaPM , AngerKE , NuccioP , LaGambinaS , WeinhouseG . Inhaled epoprostenol vs inhaled nitric oxide for refractory hypoxemia in critically ill patients. Journal of Critical Care2013;28(5):844‐8. [PUBMED: 23683572] ">Torbic 2013</a>; <a href="./references#CD007733-bbs2-0025" title="VanHeerdenPV , BlytheD , WebbSA . Inhaled aerosolized prostacyclin and nitric oxide as selective pulmonary vasodilators in ARDS ‐ a pilot study. Anaesthesia and Intensive Care1996;24(5):564‐8. [PUBMED: 8909667] ">Van Heerden 1996</a>; <a href="./references#CD007733-bbs2-0026" title="VanHeerdenPV , BardenA , MichalopoulosN , BulsaraMK , RobertsBL . Dose‐response to inhaled aerosolized prostacyclin for hypoxemia due to ARDS. Chest2000;117(3):819‐27. [PUBMED: 10713012] ">Van Heerden 2000</a>; <a href="./references#CD007733-bbs2-0027" title="VassarMJ , FletcherMP , PerryCA , HolcroftJW . Evaluation of prostaglandin E1 for prevention of respiratory failure in high risk trauma patients: a prospective clinical trial and correlation with plasma suppressive factors for neutrophil activation. Prostaglandins, Leukotrienes and Essential Fatty Acids1991;44(4):223‐31. [PUBMED: 1667693] ">Vassar 1991</a>; <a href="./references#CD007733-bbs2-0028" title="VincentJL , BraseR , SantmanF , SuterPM , McLuckieA , DhainautJF , et al. A multi‐centre, double‐blind, placebo‐controlled study of liposomal prostaglandin E1 (TLC C‐53) in patients with acute respiratory distress syndrome. Intensive Care Medicine2001;27(10):1578‐83. [PUBMED: 11685297] ">Vincent 2001</a>; <a href="./references#CD007733-bbs2-0029" title="WalmrathD , SchneiderT , PilchJ , SchermulyR , GrimmingerF , SeegerW . Effects of aerosolized prostacyclin in severe pneumonia. Impact of fibrosis. American Journal of Respiratory and Critical Care Medicine1995;151(3 Pt 1):724‐30. [PUBMED: 7881662] ">Walmrath 1995</a>; <a href="./references#CD007733-bbs2-0030" title="WalmrathD , SchneiderT , SchermulyR , OlschewskiH , GrimmingerF , SeegerW . Direct comparison of inhaled nitric oxide and aerosolized prostacyclin in acute respiratory distress syndrome. American Journal of Respiratory and Critical Care Medicine1996;153(3):991‐6. [PUBMED: 8630585] ">Walmrath 1996</a>; <a href="./references#CD007733-bbs2-0031" title="ZwisslerB , KemmingG , HablerO , KleenM , MerkelM , HallerM , et al. Inhaled prostacyclin (PGI2) versus inhaled nitric oxide in adult respiratory distress syndrome. American Journal of Respiratory and Critical Care Medicine1996;154(6 Pt 1):1671‐7. [PUBMED: 8970353] ">Zwissler 1996</a>), for the reasons detailed in the <a href="./references#CD007733-sec-0098" title="">Characteristics of excluded studies</a> table. </p> <p>One trial was an RCT enrolling only neonatal participants and was therefore excluded (<a href="./references#CD007733-bbs2-0022" title="SoodB , KeszlerM , GargM , KleinJM , OhlsR , AmbalavananN , et al. Inhaled PGE1 in neonates with hypoxemic respiratory failure: two pilot feasibility randomized clinical trials. Trials2014;15:486. [PUBMED: 25496504] ">Sood 2014</a>). </p> <p>In <a href="./references#CD007733-bbs2-0022" title="SoodB , KeszlerM , GargM , KleinJM , OhlsR , AmbalavananN , et al. Inhaled PGE1 in neonates with hypoxemic respiratory failure: two pilot feasibility randomized clinical trials. Trials2014;15:486. [PUBMED: 25496504] ">Sood 2014</a>, all seven participants INO prior to enrolment. Four participants received pulmonary vasodilators (milrinone and sildenafil), one participant, randomized to high‐dose inhaled PGE<sub>1</sub> received low‐dose inhaled PGE<sub>1</sub> for the first 24 hours, thereafter high‐dose inhaled PGE<sub>1</sub>. Five (71.43%) participants received surfactant. Five (71.43%) received neuromuscular blockade, and four (57.14%) received steroids before randomization. Six (85.71%) received extracorporeal membrane oxygenation. </p> <section id="CD007733-sec-0052"> <h5 class="title">Studies awaiting classification</h5> <p>There are no studies awaiting classification.</p> </section> <section id="CD007733-sec-0053"> <h5 class="title">Ongoing studies</h5> <p>We found no ongoing studies.</p> </section> </section> </section> <section id="CD007733-sec-0054"> <h3 class="title">Risk of bias in included studies</h3> <p>The overall quality of the two included studies was evaluated based on the major sources of bias (domains) as described in <a href="./appendices#CD007733-sec-0077">Appendix 3</a> (<a href="./references#CD007733-bbs2-0001" title="DahlemP , vanAalderenWM , deNeefM , DijkgraafMG , BosAP . Randomized controlled trial of aerosolized prostacyclin therapy in children with acute lung injury. Critical Care Medicine2004;32(4):1055‐60. [PUBMED: 15071401] ">Dahlem 2004</a>; <a href="./references#CD007733-bbs2-0002" title="SiddiquiS , SalahuddinN , ZubairS , YousufM , AzamI , GilaniAH . Use of inhaled PGE1 to improve diastolic dysfunction, LVEDP, pulmonary hypertension and hypoxia in ARDS ‐ a randomised clinical trial. Open Journal of Anesthesiology2013;3(2):109‐15. [DOI: 10.4236/ojanes.2013.32027] ">Siddiqui 2013</a>). </p> <p>We contacted the lead author of <a href="./references#CD007733-bbs2-0001" title="DahlemP , vanAalderenWM , deNeefM , DijkgraafMG , BosAP . Randomized controlled trial of aerosolized prostacyclin therapy in children with acute lung injury. Critical Care Medicine2004;32(4):1055‐60. [PUBMED: 15071401] ">Dahlem 2004</a> but he was only able to provide a limited amount of relevant information. We also contacted the authors of <a href="./references#CD007733-bbs2-0002" title="SiddiquiS , SalahuddinN , ZubairS , YousufM , AzamI , GilaniAH . Use of inhaled PGE1 to improve diastolic dysfunction, LVEDP, pulmonary hypertension and hypoxia in ARDS ‐ a randomised clinical trial. Open Journal of Anesthesiology2013;3(2):109‐15. [DOI: 10.4236/ojanes.2013.32027] ">Siddiqui 2013</a>. After further contact, we became aware of incorrect reporting on an important outcome which has been revised in this paper (see <a href="./references#CD007733-sec-0097" title="">Characteristics of included studies</a> table). </p> <p>Both <a href="./references#CD007733-bbs2-0001" title="DahlemP , vanAalderenWM , deNeefM , DijkgraafMG , BosAP . Randomized controlled trial of aerosolized prostacyclin therapy in children with acute lung injury. Critical Care Medicine2004;32(4):1055‐60. [PUBMED: 15071401] ">Dahlem 2004</a> and <a href="./references#CD007733-bbs2-0002" title="SiddiquiS , SalahuddinN , ZubairS , YousufM , AzamI , GilaniAH . Use of inhaled PGE1 to improve diastolic dysfunction, LVEDP, pulmonary hypertension and hypoxia in ARDS ‐ a randomised clinical trial. Open Journal of Anesthesiology2013;3(2):109‐15. [DOI: 10.4236/ojanes.2013.32027] ">Siddiqui 2013</a> could be considered as low risk of bias trials, despite its limitations due to size and design. For a more detailed description of individual trial methodology, see the <a href="./references#CD007733-sec-0097" title="">Characteristics of included studies</a> table. The various bias domains are presented in <a href="#CD007733-fig-0002">Figure 2</a> and <a href="#CD007733-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD007733-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies." data-id="CD007733-fig-0002" src="/cdsr/doi/10.1002/14651858.CD007733.pub3/media/CDSR/CD007733/image_n/nCD007733-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD007733-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Methodological quality summary: review authors' judgements about each methodological quality item for each included study." data-id="CD007733-fig-0003" src="/cdsr/doi/10.1002/14651858.CD007733.pub3/media/CDSR/CD007733/image_n/nCD007733-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Methodological quality summary: review authors' judgements about each methodological quality item for each included study. </p> </div> </div> </div> <section id="CD007733-sec-0055"> <h4 class="title">Allocation</h4> <p>Both trials reported generation of allocation sequence adequately (<a href="./references#CD007733-bbs2-0001" title="DahlemP , vanAalderenWM , deNeefM , DijkgraafMG , BosAP . Randomized controlled trial of aerosolized prostacyclin therapy in children with acute lung injury. Critical Care Medicine2004;32(4):1055‐60. [PUBMED: 15071401] ">Dahlem 2004</a>; <a href="./references#CD007733-bbs2-0002" title="SiddiquiS , SalahuddinN , ZubairS , YousufM , AzamI , GilaniAH . Use of inhaled PGE1 to improve diastolic dysfunction, LVEDP, pulmonary hypertension and hypoxia in ARDS ‐ a randomised clinical trial. Open Journal of Anesthesiology2013;3(2):109‐15. [DOI: 10.4236/ojanes.2013.32027] ">Siddiqui 2013</a>) (<a href="#CD007733-fig-0003">Figure 3</a>). </p> <p>Both trials reported allocation concealment adequately (<a href="./references#CD007733-bbs2-0001" title="DahlemP , vanAalderenWM , deNeefM , DijkgraafMG , BosAP . Randomized controlled trial of aerosolized prostacyclin therapy in children with acute lung injury. Critical Care Medicine2004;32(4):1055‐60. [PUBMED: 15071401] ">Dahlem 2004</a>; <a href="./references#CD007733-bbs2-0002" title="SiddiquiS , SalahuddinN , ZubairS , YousufM , AzamI , GilaniAH . Use of inhaled PGE1 to improve diastolic dysfunction, LVEDP, pulmonary hypertension and hypoxia in ARDS ‐ a randomised clinical trial. Open Journal of Anesthesiology2013;3(2):109‐15. [DOI: 10.4236/ojanes.2013.32027] ">Siddiqui 2013</a>) (<a href="#CD007733-fig-0003">Figure 3</a>). </p> </section> <section id="CD007733-sec-0056"> <h4 class="title">Blinding</h4> <p><a href="./references#CD007733-bbs2-0001" title="DahlemP , vanAalderenWM , deNeefM , DijkgraafMG , BosAP . Randomized controlled trial of aerosolized prostacyclin therapy in children with acute lung injury. Critical Care Medicine2004;32(4):1055‐60. [PUBMED: 15071401] ">Dahlem 2004</a> provided sufficient data to be categorized as double‐blinded (low risk of bias). In <a href="./references#CD007733-bbs2-0002" title="SiddiquiS , SalahuddinN , ZubairS , YousufM , AzamI , GilaniAH . Use of inhaled PGE1 to improve diastolic dysfunction, LVEDP, pulmonary hypertension and hypoxia in ARDS ‐ a randomised clinical trial. Open Journal of Anesthesiology2013;3(2):109‐15. [DOI: 10.4236/ojanes.2013.32027] ">Siddiqui 2013</a>, all investigators, staff and participants were masked to outcome measurements and allocation (low risk of bias) (<a href="#CD007733-fig-0003">Figure 3</a>). </p> </section> <section id="CD007733-sec-0057"> <h4 class="title">Incomplete outcome data</h4> <p>Both <a href="./references#CD007733-bbs2-0001" title="DahlemP , vanAalderenWM , deNeefM , DijkgraafMG , BosAP . Randomized controlled trial of aerosolized prostacyclin therapy in children with acute lung injury. Critical Care Medicine2004;32(4):1055‐60. [PUBMED: 15071401] ">Dahlem 2004</a> and <a href="./references#CD007733-bbs2-0002" title="SiddiquiS , SalahuddinN , ZubairS , YousufM , AzamI , GilaniAH . Use of inhaled PGE1 to improve diastolic dysfunction, LVEDP, pulmonary hypertension and hypoxia in ARDS ‐ a randomised clinical trial. Open Journal of Anesthesiology2013;3(2):109‐15. [DOI: 10.4236/ojanes.2013.32027] ">Siddiqui 2013</a> had adequate follow‐up (low risk) (<a href="#CD007733-fig-0003">Figure 3</a>). There appeared to be complete follow‐up for the primary outcome in <a href="./references#CD007733-bbs2-0001" title="DahlemP , vanAalderenWM , deNeefM , DijkgraafMG , BosAP . Randomized controlled trial of aerosolized prostacyclin therapy in children with acute lung injury. Critical Care Medicine2004;32(4):1055‐60. [PUBMED: 15071401] ">Dahlem 2004</a>, but only for the length of follow‐up, which was 28 days. <a href="./references#CD007733-bbs2-0002" title="SiddiquiS , SalahuddinN , ZubairS , YousufM , AzamI , GilaniAH . Use of inhaled PGE1 to improve diastolic dysfunction, LVEDP, pulmonary hypertension and hypoxia in ARDS ‐ a randomised clinical trial. Open Journal of Anesthesiology2013;3(2):109‐15. [DOI: 10.4236/ojanes.2013.32027] ">Siddiqui 2013</a> excluded five participants after randomization because they died before receiving the intervention. The remaining randomized participants seem accounted for in the tables. The authors performed analysis according to the ITT method in both trials (<a href="./references#CD007733-bbs2-0001" title="DahlemP , vanAalderenWM , deNeefM , DijkgraafMG , BosAP . Randomized controlled trial of aerosolized prostacyclin therapy in children with acute lung injury. Critical Care Medicine2004;32(4):1055‐60. [PUBMED: 15071401] ">Dahlem 2004</a>; <a href="./references#CD007733-bbs2-0002" title="SiddiquiS , SalahuddinN , ZubairS , YousufM , AzamI , GilaniAH . Use of inhaled PGE1 to improve diastolic dysfunction, LVEDP, pulmonary hypertension and hypoxia in ARDS ‐ a randomised clinical trial. Open Journal of Anesthesiology2013;3(2):109‐15. [DOI: 10.4236/ojanes.2013.32027] ">Siddiqui 2013</a>). However, in <a href="./references#CD007733-bbs2-0002" title="SiddiquiS , SalahuddinN , ZubairS , YousufM , AzamI , GilaniAH . Use of inhaled PGE1 to improve diastolic dysfunction, LVEDP, pulmonary hypertension and hypoxia in ARDS ‐ a randomised clinical trial. Open Journal of Anesthesiology2013;3(2):109‐15. [DOI: 10.4236/ojanes.2013.32027] ">Siddiqui 2013</a>, we became aware of inadequate reporting of data on the pulmonary artery pressure values (see <a href="./references#CD007733-sec-0097" title="">Characteristics of included studies</a> table). </p> </section> <section id="CD007733-sec-0058"> <h4 class="title">Selective reporting</h4> <p>We were unable to retrieve the original protocol of <a href="./references#CD007733-bbs2-0001" title="DahlemP , vanAalderenWM , deNeefM , DijkgraafMG , BosAP . Randomized controlled trial of aerosolized prostacyclin therapy in children with acute lung injury. Critical Care Medicine2004;32(4):1055‐60. [PUBMED: 15071401] ">Dahlem 2004</a> and thus were unable to examine selective outcome (unclear risk of bias). The trial registration of <a href="./references#CD007733-bbs2-0002" title="SiddiquiS , SalahuddinN , ZubairS , YousufM , AzamI , GilaniAH . Use of inhaled PGE1 to improve diastolic dysfunction, LVEDP, pulmonary hypertension and hypoxia in ARDS ‐ a randomised clinical trial. Open Journal of Anesthesiology2013;3(2):109‐15. [DOI: 10.4236/ojanes.2013.32027] ">Siddiqui 2013</a> was available on ClinicalTrials.gov (low risk of bias) (see <a href="./references#CD007733-sec-0097" title="">Characteristics of included studies</a> table). </p> </section> <section id="CD007733-sec-0059"> <h4 class="title">Other potential sources of bias</h4> <p>Neither trial was industry funded (<a href="./references#CD007733-bbs2-0001" title="DahlemP , vanAalderenWM , deNeefM , DijkgraafMG , BosAP . Randomized controlled trial of aerosolized prostacyclin therapy in children with acute lung injury. Critical Care Medicine2004;32(4):1055‐60. [PUBMED: 15071401] ">Dahlem 2004</a>; <a href="./references#CD007733-bbs2-0002" title="SiddiquiS , SalahuddinN , ZubairS , YousufM , AzamI , GilaniAH . Use of inhaled PGE1 to improve diastolic dysfunction, LVEDP, pulmonary hypertension and hypoxia in ARDS ‐ a randomised clinical trial. Open Journal of Anesthesiology2013;3(2):109‐15. [DOI: 10.4236/ojanes.2013.32027] ">Siddiqui 2013</a>). Sample size calculation was not reported and the trials were not powered to show a statistically significant benefit in primary outcome measures. </p> <p>We were unable to conduct analyses such as the funnel plot, the arcsine‐Thompson test as proposed by Rücker (<a href="./references#CD007733-bbs2-0068" title="RückerG , SchwarzerG , CarpenterJ . Arcsine test for publication bias in meta‐analyses with binary outcomes. Statistics in Medicine2008;27(5):746‐63. [PUBMED: 17592831] ">Rücker 2008</a>), or the Egger's regression intercept test as only two RCTs were included, one of which was a cross‐over trial (<a href="./references#CD007733-bbs2-0001" title="DahlemP , vanAalderenWM , deNeefM , DijkgraafMG , BosAP . Randomized controlled trial of aerosolized prostacyclin therapy in children with acute lung injury. Critical Care Medicine2004;32(4):1055‐60. [PUBMED: 15071401] ">Dahlem 2004</a>), and the second did not present data on mortality (<a href="./references#CD007733-bbs2-0002" title="SiddiquiS , SalahuddinN , ZubairS , YousufM , AzamI , GilaniAH . Use of inhaled PGE1 to improve diastolic dysfunction, LVEDP, pulmonary hypertension and hypoxia in ARDS ‐ a randomised clinical trial. Open Journal of Anesthesiology2013;3(2):109‐15. [DOI: 10.4236/ojanes.2013.32027] ">Siddiqui 2013</a>). </p> </section> </section> <section id="CD007733-sec-0060"> <h3 class="title" id="CD007733-sec-0060">Effects of interventions</h3> <p>See: <a href="./full#CD007733-tbl-0001"><b>Summary of findings for the main comparison</b> Aerosolized prostacyclin compared to placebo for acute respiratory distress syndrome (ARDS)</a> </p> <section id="CD007733-sec-0061"> <h4 class="title">Primary outcomes</h4> <section id="CD007733-sec-0062"> <h5 class="title">Overall mortality</h5> <p>As described above, data from <a href="./references#CD007733-bbs2-0001" title="DahlemP , vanAalderenWM , deNeefM , DijkgraafMG , BosAP . Randomized controlled trial of aerosolized prostacyclin therapy in children with acute lung injury. Critical Care Medicine2004;32(4):1055‐60. [PUBMED: 15071401] ">Dahlem 2004</a> were not eligible for meta‐analysis due to the cross‐over design. </p> <p>After completion of both treatment sequences, 2/8 participants in the intervention group died compared to 1/6 participants in the control group (RR 1.50, 95% CI 0.17 to 12.94; <a href="./references#CD007733-sec-0097" title="">Characteristics of included studies</a> table). Due to the cross‐over design of this trial, the results merely reflect the effect of the drug administration sequence rather than the intervention by itself. The results are thus not considered as a valid effect estimate for the primary endpoint of this review. </p> <p>Furthermore, since no data were available from <a href="./references#CD007733-bbs2-0002" title="SiddiquiS , SalahuddinN , ZubairS , YousufM , AzamI , GilaniAH . Use of inhaled PGE1 to improve diastolic dysfunction, LVEDP, pulmonary hypertension and hypoxia in ARDS ‐ a randomised clinical trial. Open Journal of Anesthesiology2013;3(2):109‐15. [DOI: 10.4236/ojanes.2013.32027] ">Siddiqui 2013</a>, there was no option for meta‐analysis. However, no statistically significant difference was found in <a href="./references#CD007733-bbs2-0001" title="DahlemP , vanAalderenWM , deNeefM , DijkgraafMG , BosAP . Randomized controlled trial of aerosolized prostacyclin therapy in children with acute lung injury. Critical Care Medicine2004;32(4):1055‐60. [PUBMED: 15071401] ">Dahlem 2004</a> when comparing the two groups (<a href="./full#CD007733-tbl-0001">summary of findings Table for the main comparison</a>; <a href="./references#CD007733-sec-0097" title="">Characteristics of included studies</a> table). This outcome was downgraded from high to low quality of evidence due to limitations in design (small sample size, few events, cross‐over design) suggesting high likelihood of bias, indirectness of evidence and high probability of publication bias. (<a href="./references#CD007733-bbs2-0001" title="DahlemP , vanAalderenWM , deNeefM , DijkgraafMG , BosAP . Randomized controlled trial of aerosolized prostacyclin therapy in children with acute lung injury. Critical Care Medicine2004;32(4):1055‐60. [PUBMED: 15071401] ">Dahlem 2004</a>). </p> <section id="CD007733-sec-0063"> <h6 class="title">Sensitivity and subgroup analyses</h6> <p>We were unable to conduct our prespecified sensitivity and subgroup analyses due to lack of included RCTs. Additionally, the authors of the included trials conducted very few analyses relevant to our systematic review (<a href="./references#CD007733-bbs2-0001" title="DahlemP , vanAalderenWM , deNeefM , DijkgraafMG , BosAP . Randomized controlled trial of aerosolized prostacyclin therapy in children with acute lung injury. Critical Care Medicine2004;32(4):1055‐60. [PUBMED: 15071401] ">Dahlem 2004</a>; <a href="./references#CD007733-bbs2-0002" title="SiddiquiS , SalahuddinN , ZubairS , YousufM , AzamI , GilaniAH . Use of inhaled PGE1 to improve diastolic dysfunction, LVEDP, pulmonary hypertension and hypoxia in ARDS ‐ a randomised clinical trial. Open Journal of Anesthesiology2013;3(2):109‐15. [DOI: 10.4236/ojanes.2013.32027] ">Siddiqui 2013</a>). </p> <p><b>Bias assessment:</b> we were unable to conduct any relevant estimate of the intervention effect based on random sequence generation, allocation concealment, blinding, follow‐up, sample size calculation, early stopping, funding bias, other bias and the overall risk of bias since we only managed to find two relevant RCTs. </p> </section> </section> </section> <section id="CD007733-sec-0064"> <h4 class="title">Secondary outcomes</h4> <p><b>Respiratory outcomes:</b><a href="./references#CD007733-bbs2-0001" title="DahlemP , vanAalderenWM , deNeefM , DijkgraafMG , BosAP . Randomized controlled trial of aerosolized prostacyclin therapy in children with acute lung injury. Critical Care Medicine2004;32(4):1055‐60. [PUBMED: 15071401] ">Dahlem 2004</a> reported a 26% improvement in oxygenation index at 30 ng/kg/minute compared with placebo but there was no information on the oxygenation index based on different days. However, it is important to remember the limitations of this trial due to its design characteristics. <a href="./references#CD007733-bbs2-0002" title="SiddiquiS , SalahuddinN , ZubairS , YousufM , AzamI , GilaniAH . Use of inhaled PGE1 to improve diastolic dysfunction, LVEDP, pulmonary hypertension and hypoxia in ARDS ‐ a randomised clinical trial. Open Journal of Anesthesiology2013;3(2):109‐15. [DOI: 10.4236/ojanes.2013.32027] ">Siddiqui 2013</a> reported a non‐significant improvement in PaO<sub>2</sub>/ FiO<sub>2</sub> ratio (MD ‐25.35, 95% CI ‐60.48 to 9.78; 1 RCT, 67 participants, very low quality of evidence) (<a href="./full#CD007733-tbl-0001">summary of findings Table for the main comparison</a>). The outcome was downgraded two levels (from high to very low quality of evidence) for very serious imprecision due to small sample size, few events and wide 95% CI suggesting high likelihood of bias and indirectness of evidence. (<a href="./references#CD007733-bbs2-0002" title="SiddiquiS , SalahuddinN , ZubairS , YousufM , AzamI , GilaniAH . Use of inhaled PGE1 to improve diastolic dysfunction, LVEDP, pulmonary hypertension and hypoxia in ARDS ‐ a randomised clinical trial. Open Journal of Anesthesiology2013;3(2):109‐15. [DOI: 10.4236/ojanes.2013.32027] ">Siddiqui 2013</a>). </p> <p><b>Vascular outcomes:</b> after further correspondence with the lead author of <a href="./references#CD007733-bbs2-0002" title="SiddiquiS , SalahuddinN , ZubairS , YousufM , AzamI , GilaniAH . Use of inhaled PGE1 to improve diastolic dysfunction, LVEDP, pulmonary hypertension and hypoxia in ARDS ‐ a randomised clinical trial. Open Journal of Anesthesiology2013;3(2):109‐15. [DOI: 10.4236/ojanes.2013.32027] ">Siddiqui 2013</a>, it became apparent that we were unable to carry out any meaningful analyses on our predefined secondary outcomes such as pulmonary artery pressure due to incorrect reporting (see <a href="./references#CD007733-sec-0097" title="">Characteristics of included studies</a> table). </p> <p>Outcomes such as severity of illness, resolution of organ dysfunction, length of stay in ICU or hospital, quality of life assessment and cost‐benefit analyses were not conducted by the authors. </p> <p><b>Adverse events and complications:</b> the authors did not encounter any adverse events such as bleeding, organ dysfunction, airway reactivity or adverse events unrelated to the intervention (<a href="./references#CD007733-bbs2-0001" title="DahlemP , vanAalderenWM , deNeefM , DijkgraafMG , BosAP . Randomized controlled trial of aerosolized prostacyclin therapy in children with acute lung injury. Critical Care Medicine2004;32(4):1055‐60. [PUBMED: 15071401] ">Dahlem 2004</a>; <a href="./references#CD007733-bbs2-0002" title="SiddiquiS , SalahuddinN , ZubairS , YousufM , AzamI , GilaniAH . Use of inhaled PGE1 to improve diastolic dysfunction, LVEDP, pulmonary hypertension and hypoxia in ARDS ‐ a randomised clinical trial. Open Journal of Anesthesiology2013;3(2):109‐15. [DOI: 10.4236/ojanes.2013.32027] ">Siddiqui 2013</a>). The outcome was downgraded two levels (from high to very low quality of evidence) for very serious imprecision due to small sample size and few events and since only descriptive assessment of safety and adverse events were provided in the included trials with no data being available for meta‐analyses. </p> <p><b>Quality of life and cost‐benefit analysis:</b> the authors of both trials did not conduct any quality of life assessment or cost‐benefit analysis (<a href="./references#CD007733-bbs2-0001" title="DahlemP , vanAalderenWM , deNeefM , DijkgraafMG , BosAP . Randomized controlled trial of aerosolized prostacyclin therapy in children with acute lung injury. Critical Care Medicine2004;32(4):1055‐60. [PUBMED: 15071401] ">Dahlem 2004</a>; <a href="./references#CD007733-bbs2-0002" title="SiddiquiS , SalahuddinN , ZubairS , YousufM , AzamI , GilaniAH . Use of inhaled PGE1 to improve diastolic dysfunction, LVEDP, pulmonary hypertension and hypoxia in ARDS ‐ a randomised clinical trial. Open Journal of Anesthesiology2013;3(2):109‐15. [DOI: 10.4236/ojanes.2013.32027] ">Siddiqui 2013</a>). </p> <p><b>Trial sequential analysis:</b> trial sequential analysis was not considered appropriate since the one trial was cross‐over (<a href="./references#CD007733-bbs2-0001" title="DahlemP , vanAalderenWM , deNeefM , DijkgraafMG , BosAP . Randomized controlled trial of aerosolized prostacyclin therapy in children with acute lung injury. Critical Care Medicine2004;32(4):1055‐60. [PUBMED: 15071401] ">Dahlem 2004</a>) and its inclusion in this review may be considered debatable and since the other RCT was of a size that the proportion of the required information size was probably less than 1%. However, we tried to estimate the required information size for a conclusive meta‐analysis considering a type 1 error risk of 5%, a type 2 error risk of 20%, an anticipated relative risk reduction of 20%, and a mortality rate in the control group of a paediatric population of about 20% and 40% in the adult population. </p> <p>The required information size for a paediatric population, depending on the level of heterogeneity adjustment, was between 2897 (I<sup>2</sup> = 0) and 3862 (I<sup>2</sup> = 25%). The required information size for the adult population with the same level of heterogeneity was between 1132 (I<sup>2</sup> = 0) and 1508 (I<sup>2</sup> = 25%). </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD007733-sec-0065" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD007733-sec-0065"></div> <p>In this updated systematic review, we were only able to include two trials with 81 critically ill participants with ARDS that assessed the effect of aerosolized prostacyclin (<a href="./references#CD007733-bbs2-0001" title="DahlemP , vanAalderenWM , deNeefM , DijkgraafMG , BosAP . Randomized controlled trial of aerosolized prostacyclin therapy in children with acute lung injury. Critical Care Medicine2004;32(4):1055‐60. [PUBMED: 15071401] ">Dahlem 2004</a>; <a href="./references#CD007733-bbs2-0002" title="SiddiquiS , SalahuddinN , ZubairS , YousufM , AzamI , GilaniAH . Use of inhaled PGE1 to improve diastolic dysfunction, LVEDP, pulmonary hypertension and hypoxia in ARDS ‐ a randomised clinical trial. Open Journal of Anesthesiology2013;3(2):109‐15. [DOI: 10.4236/ojanes.2013.32027] ">Siddiqui 2013</a>). </p> <p><a href="./references#CD007733-bbs2-0001" title="DahlemP , vanAalderenWM , deNeefM , DijkgraafMG , BosAP . Randomized controlled trial of aerosolized prostacyclin therapy in children with acute lung injury. Critical Care Medicine2004;32(4):1055‐60. [PUBMED: 15071401] ">Dahlem 2004</a> was a cross‐over trial, not considered eligible for meta‐analyses. This is insufficient to demonstrate any benefits or harms of inhaled prostacyclin therapy. We found no ongoing trials. </p> <p>Based on the very limited data available, we were unable to show any benefits of aerosolized prostacyclin on survival or other clinical outcomes. The sparse data on mortality were not promising but were not evidence of the absence of a beneficial effect; neither did the data suggest the degree of a potentially beneficial or detrimental effect of inhaled prostacyclin. </p> <p><a href="./references#CD007733-bbs2-0001" title="DahlemP , vanAalderenWM , deNeefM , DijkgraafMG , BosAP . Randomized controlled trial of aerosolized prostacyclin therapy in children with acute lung injury. Critical Care Medicine2004;32(4):1055‐60. [PUBMED: 15071401] ">Dahlem 2004</a> found the oxygenation index significantly improved in the prostacyclin group. <a href="./references#CD007733-bbs2-0002" title="SiddiquiS , SalahuddinN , ZubairS , YousufM , AzamI , GilaniAH . Use of inhaled PGE1 to improve diastolic dysfunction, LVEDP, pulmonary hypertension and hypoxia in ARDS ‐ a randomised clinical trial. Open Journal of Anesthesiology2013;3(2):109‐15. [DOI: 10.4236/ojanes.2013.32027] ">Siddiqui 2013</a> found a non‐significant improvement in the PaO<sub>2</sub>/FiO<sub>2</sub> ratio (P = 0.16) in the prostacyclin group. These two parameters are only surrogate outcomes and it is uncertain whether they predict any true clinical benefits, as previously illustrated by trials examining the role of INO (<a href="./references#CD007733-bbs2-0033" title="AdhikariNK , BurnsKE , FriedrichJO , GrantonJT , CookDJ , MeadeMO . Effect of nitric oxide on oxygenation and mortality in acute lung injury: systematic review and meta‐analysis. BMJ2007;334(7597):779. [PUBMED: 17383982] ">Adhikari 2007</a>; <a href="./references#CD007733-bbs2-0048" title="GebistorfF , KaramO , WetterslevJ , AfshariA . Inhaled nitric oxide for acute respiratory distress syndrome (ARDS) in children and adults. Cochrane Database of Systematic Reviews2016, Issue 6. [DOI: 10.1002/14651858.CD002787.pub3] ">Gebistorf 2016</a>). </p> <p>These results must therefore be interpreted with caution due to design issues, risk of bias, sample size limitations and the choice of surrogate outcomes. </p> <p>The evidence for inhaled prostacyclin in adults with ARDS is currently based on observational studies and case reports examining the role of inhaled prostacyclin as a single intervention. Compared to INO or in conjunction with INO, all indicated improved oxygenation but with few data on survival (<a href="./references#CD007733-bbs2-0010" title="DomenighettiG , StrickerH , WaldispuehlB . Nebulized prostacyclin (PGI2) in acute respiratory distress syndrome: impact of primary (pulmonary injury) and secondary (extrapulmonary injury) disease on gas exchange response. Critical Care Medicine2001;29(1):57‐62. [PUBMED: 11176161] ">Domenighetti 2001</a>; <a href="./references#CD007733-bbs2-0015" title="MeyerJ , TheilmeierG , VanAkenH , BoneHG , BusseH , WaurickR , et al. Inhaled prostaglandin E1 for treatment of acute lung injury in severe multiple organ failure. Anesthesia and Analgesia1998;86(4):753‐8. [PUBMED: 9539597] ">Meyer 1998</a>; <a href="./references#CD007733-bbs2-0018" title="PutensenC , HörmannC , KleinsasserA , Putensen‐HimmerG . Cardiopulmonary effects of aerosolized prostaglandin E1 and nitric oxide inhalation in patients with acute respiratory distress syndrome. American Journal of Respiratory and Critical Care Medicine1998;157(6 Pt 1):1743‐7. [PUBMED: 9620900] ">Putensen 1998</a>; <a href="./references#CD007733-bbs2-0025" title="VanHeerdenPV , BlytheD , WebbSA . Inhaled aerosolized prostacyclin and nitric oxide as selective pulmonary vasodilators in ARDS ‐ a pilot study. Anaesthesia and Intensive Care1996;24(5):564‐8. [PUBMED: 8909667] ">Van Heerden 1996</a>; <a href="./references#CD007733-bbs2-0026" title="VanHeerdenPV , BardenA , MichalopoulosN , BulsaraMK , RobertsBL . Dose‐response to inhaled aerosolized prostacyclin for hypoxemia due to ARDS. Chest2000;117(3):819‐27. [PUBMED: 10713012] ">Van Heerden 2000</a>; <a href="./references#CD007733-bbs2-0030" title="WalmrathD , SchneiderT , SchermulyR , OlschewskiH , GrimmingerF , SeegerW . Direct comparison of inhaled nitric oxide and aerosolized prostacyclin in acute respiratory distress syndrome. American Journal of Respiratory and Critical Care Medicine1996;153(3):991‐6. [PUBMED: 8630585] ">Walmrath 1996</a>; <a href="./references#CD007733-bbs2-0031" title="ZwisslerB , KemmingG , HablerO , KleenM , MerkelM , HallerM , et al. Inhaled prostacyclin (PGI2) versus inhaled nitric oxide in adult respiratory distress syndrome. American Journal of Respiratory and Critical Care Medicine1996;154(6 Pt 1):1671‐7. [PUBMED: 8970353] ">Zwissler 1996</a>). </p> <p>One systematic review identified seven RCTs which applied intravenous PGE<sub>1</sub> for the treatment of ARDS (<a href="./references#CD007733-bbs2-0032" title="AdhikariN , BurnsKE , MeadeMO . Pharmacologic therapies for adults with acute lung injury and acute respiratory distress syndrome. Cochrane Database of Systematic Reviews2004, Issue 4. [DOI: 10.1002/14651858.CD004477.pub2] ">Adhikari 2004</a>). The authors found no evidence to support the routine administration of PGE<sub>1</sub>. However, there are important pharmacological differences that might not justify a direct comparison of intravenous and aerosolized treatment of PGE<sub>1</sub>. Intravenous PGE<sub>1</sub> is a vasodilator that decreases both pulmonary and systemic blood pressure and at the same time increases the venous admixture. Inhaled prostacyclin is believed to selectively dilate the pulmonary vasculature in ventilated lung areas, thus improving the ventilation/perfusion ratio and oxygenation (<a href="./references#CD007733-bbs2-0015" title="MeyerJ , TheilmeierG , VanAkenH , BoneHG , BusseH , WaurickR , et al. Inhaled prostaglandin E1 for treatment of acute lung injury in severe multiple organ failure. Anesthesia and Analgesia1998;86(4):753‐8. [PUBMED: 9539597] ">Meyer 1998</a>). </p> <section id="CD007733-sec-0066"> <h3 class="title" id="CD007733-sec-0066">Summary of main results</h3> <p>This updated systematic review was unable to show any beneficial effect of aerosolized prostacyclin despite indications of improved oxygenation index, due to the limited number of RCTs at this stage. We were unable to conduct our prespecified multiple subgroup and sensitivity analyses. There is currently a lack of evidence to support the routine use of aerosolized prostacyclin for ARDS. </p> </section> <section id="CD007733-sec-0067"> <h3 class="title" id="CD007733-sec-0067">Quality of the evidence</h3> <p>We planned to apply several statistical methods to explore and reduce the risk of bias and risk of random error, such as complete case analysis, trial sequential analysis, overall methodological bias assessment and analyses of various relevant clinical and physiological outcomes. However, since only two trials were included in this updated review (<a href="./references#CD007733-bbs2-0001" title="DahlemP , vanAalderenWM , deNeefM , DijkgraafMG , BosAP . Randomized controlled trial of aerosolized prostacyclin therapy in children with acute lung injury. Critical Care Medicine2004;32(4):1055‐60. [PUBMED: 15071401] ">Dahlem 2004</a>; <a href="./references#CD007733-bbs2-0002" title="SiddiquiS , SalahuddinN , ZubairS , YousufM , AzamI , GilaniAH . Use of inhaled PGE1 to improve diastolic dysfunction, LVEDP, pulmonary hypertension and hypoxia in ARDS ‐ a randomised clinical trial. Open Journal of Anesthesiology2013;3(2):109‐15. [DOI: 10.4236/ojanes.2013.32027] ">Siddiqui 2013</a>), we were unable to carry out the analyses. Thus, we tried to estimate the required information for a conclusive meta‐analysis on this intervention in both paediatric and adult populations, with and without a 25% heterogeneity adjustment. </p> <p>Our systematic review had several potential limitations. The findings and interpretations were limited by the quality and quantity of the available evidence. The risk of bias of the included trials was mainly assessed by using the published data, which ultimately may not reflect the truth. Also, our estimation of a required information size makes it possible to conclude that the risk of random error in the meta‐analysis is both imminent and manifest, as less than 1% of the required information size was actually randomized. </p> </section> <section id="CD007733-sec-0068"> <h3 class="title" id="CD007733-sec-0068">Potential biases in the review process</h3> <p>Since there is no previous systematic review on this topic, we were unaware of the number of existing trials. Most of the review authors were familiar with this intervention from their experience in various ICU settings. However, this did not influence our assessment of the existing data and to our knowledge there was no other additional bias in the review process. </p> </section> <section id="CD007733-sec-0069"> <h3 class="title" id="CD007733-sec-0069">Agreements and disagreements with other studies or reviews</h3> <p>One systematic review and meta‐analysis by Fuller and colleagues included 25 publications in the analysis, including: prospective, non‐randomized interventional studies, observational cohort studies, case series and case studies (<a href="./references#CD007733-bbs2-0047" title="FullerBM , MohrNM , SkrupkyL , FowlerS , KollefMH , CarpenterCR . The use of inhaled prostaglandins in patients with ARDS: a systematic review and meta‐analysis. Chest2015;147(6):1510‐22. [PUBMED: 25742022] ">Fuller 2015</a>). The authors found that inhaled prostaglandins improved oxygenation and decreased pulmonary artery pressures and may be associated with adverse events. There was reported mortality in 17 of the 25 included studies and overall reported mortality was 295/522 (56.5%) people with ARDS receiving inhaled prostaglandins. </p> <p>Fuller and colleagues found the same two RCTs as our search (<a href="./references#CD007733-bbs2-0001" title="DahlemP , vanAalderenWM , deNeefM , DijkgraafMG , BosAP . Randomized controlled trial of aerosolized prostacyclin therapy in children with acute lung injury. Critical Care Medicine2004;32(4):1055‐60. [PUBMED: 15071401] ">Dahlem 2004</a>; <a href="./references#CD007733-bbs2-0002" title="SiddiquiS , SalahuddinN , ZubairS , YousufM , AzamI , GilaniAH . Use of inhaled PGE1 to improve diastolic dysfunction, LVEDP, pulmonary hypertension and hypoxia in ARDS ‐ a randomised clinical trial. Open Journal of Anesthesiology2013;3(2):109‐15. [DOI: 10.4236/ojanes.2013.32027] ">Siddiqui 2013</a>), and described them with very brief exposure to study drug and no participant‐centred outcomes. They made no conclusions on the basis of the two trials separately. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD007733-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007733.pub3/media/CDSR/CD007733/urn:x-wiley:14651858:media:CD007733:CD007733-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007733.pub3/media/CDSR/CD007733/image_t/tCD007733-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD007733-fig-0001" src="/cdsr/doi/10.1002/14651858.CD007733.pub3/media/CDSR/CD007733/image_n/nCD007733-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007733.pub3/full#CD007733-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007733.pub3/media/CDSR/CD007733/image_n/nCD007733-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007733-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007733.pub3/media/CDSR/CD007733/urn:x-wiley:14651858:media:CD007733:CD007733-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007733.pub3/media/CDSR/CD007733/image_t/tCD007733-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies." data-id="CD007733-fig-0002" src="/cdsr/doi/10.1002/14651858.CD007733.pub3/media/CDSR/CD007733/image_n/nCD007733-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007733.pub3/full#CD007733-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007733.pub3/media/CDSR/CD007733/image_n/nCD007733-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007733-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007733.pub3/media/CDSR/CD007733/urn:x-wiley:14651858:media:CD007733:CD007733-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007733.pub3/media/CDSR/CD007733/image_t/tCD007733-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Methodological quality summary: review authors' judgements about each methodological quality item for each included study." data-id="CD007733-fig-0003" src="/cdsr/doi/10.1002/14651858.CD007733.pub3/media/CDSR/CD007733/image_n/nCD007733-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Methodological quality summary: review authors' judgements about each methodological quality item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007733.pub3/full#CD007733-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007733.pub3/media/CDSR/CD007733/image_n/nCD007733-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD007733-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Aerosolized prostacyclin compared to placebo for acute respiratory distress syndrome (ARDS)</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>Aerosolized prostacyclin compared to placebo for acute respiratory distress syndrome (ARDS) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with ARDS </p> <p><b>Setting:</b> intensive care unit in the Netherlands and Pakistan </p> <p><b>Intervention:</b> aerosolized prostacyclin </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with aerosolized prostacyclin</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Mortality</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.50<br/> (0.17 to 12.94) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>14<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>1,2,3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Only 1 small paediatric trial with cross‐over design provided mortality data (<a href="./references#CD007733-bbs2-0001" title="DahlemP , vanAalderenWM , deNeefM , DijkgraafMG , BosAP . Randomized controlled trial of aerosolized prostacyclin therapy in children with acute lung injury. Critical Care Medicine2004;32(4):1055‐60. [PUBMED: 15071401] ">Dahlem 2004</a>). Thus, no meta‐analysis carried out. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>167 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>250 per 1000<br/> (28 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PaO<sub>2</sub>/FiO<sub>2</sub> ratio<sup>5</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 25.35 lower<br/> (60.48 lower to 9.78 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Only 1 trial provided data (<a href="./references#CD007733-bbs2-0002" title="SiddiquiS , SalahuddinN , ZubairS , YousufM , AzamI , GilaniAH . Use of inhaled PGE1 to improve diastolic dysfunction, LVEDP, pulmonary hypertension and hypoxia in ARDS ‐ a randomised clinical trial. Open Journal of Anesthesiology2013;3(2):109‐15. [DOI: 10.4236/ojanes.2013.32027] ">Siddiqui 2013</a>). Thus, no meta‐analysis was carried out. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Improvement in mean pulmonary arterial pressure</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data is available for meta‐analysis (<a href="./references#CD007733-sec-0097" title="">Characteristics of included studies</a>, <a href="./references#CD007733-bbs2-0002" title="SiddiquiS , SalahuddinN , ZubairS , YousufM , AzamI , GilaniAH . Use of inhaled PGE1 to improve diastolic dysfunction, LVEDP, pulmonary hypertension and hypoxia in ARDS ‐ a randomised clinical trial. Open Journal of Anesthesiology2013;3(2):109‐15. [DOI: 10.4236/ojanes.2013.32027] ">Siddiqui 2013</a>) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events<sup>7</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81</p> <p>(2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>8</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Only descriptive assessment of safety with no available data to carry out meaningful analyses (<a href="./references#CD007733-bbs2-0001" title="DahlemP , vanAalderenWM , deNeefM , DijkgraafMG , BosAP . Randomized controlled trial of aerosolized prostacyclin therapy in children with acute lung injury. Critical Care Medicine2004;32(4):1055‐60. [PUBMED: 15071401] ">Dahlem 2004</a>; <a href="./references#CD007733-bbs2-0002" title="SiddiquiS , SalahuddinN , ZubairS , YousufM , AzamI , GilaniAH . Use of inhaled PGE1 to improve diastolic dysfunction, LVEDP, pulmonary hypertension and hypoxia in ARDS ‐ a randomised clinical trial. Open Journal of Anesthesiology2013;3(2):109‐15. [DOI: 10.4236/ojanes.2013.32027] ">Siddiqui 2013</a>). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>FiO<sub>2</sub>:</b> fraction of inspired oxygen; <b>MD:</b> mean difference; <b>PaO<sub>2</sub>:</b> partial pressure of oxygen in arterial blood; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Mortality at 28 to 30 days. </p> <p><sup>2</sup>Required information size for paediatric population depending on the level of heterogeneity adjustment was between 2897 (I<sub>2</sub> = 0) and 3862 (I<sub>2</sub> = 25%).<br/> <sup>3</sup>Required information size for the adult population depending on the same level of heterogeneity was between 1132 (I<sub>2</sub> = 0) and 1508 (I<sub>2</sub> = 25%). </p> <p><sup>4</sup>This outcome was downgraded from high to low quality of evidence due to limitations in design (small sample size, few events, cross‐over design) suggesting high likelihood of bias, indirectness of evidence and high probability of publication bias. (<a href="./references#CD007733-bbs2-0001" title="DahlemP , vanAalderenWM , deNeefM , DijkgraafMG , BosAP . Randomized controlled trial of aerosolized prostacyclin therapy in children with acute lung injury. Critical Care Medicine2004;32(4):1055‐60. [PUBMED: 15071401] ">Dahlem 2004</a>). </p> <p><sup>5</sup>Despite the fact that biochemical markers of clinical outcomes are often not included in SoF tables, we have chosen to include this outcomes since it is widely used in clinical practice to guide treatment. </p> <p><sup>6</sup>The outcome was downgraded two levels (from high to very low quality of evidence) for very serious imprecision due to small sample size, few events and wide 95% CI suggesting high likelihood of bias and indirectness of evidence. (<a href="./references#CD007733-bbs2-0002" title="SiddiquiS , SalahuddinN , ZubairS , YousufM , AzamI , GilaniAH . Use of inhaled PGE1 to improve diastolic dysfunction, LVEDP, pulmonary hypertension and hypoxia in ARDS ‐ a randomised clinical trial. Open Journal of Anesthesiology2013;3(2):109‐15. [DOI: 10.4236/ojanes.2013.32027] ">Siddiqui 2013</a>). </p> <p><sup>7</sup>Adverse events such as bleeding or organ dysfunction </p> <p><sup>8</sup>The outcome was downgraded two levels (from high to very low quality of evidence) for very serious imprecision due to small sample size and few events and since only descriptive assessment of safety and adverse events were provided in the included trials with no data being available for meta‐analyses. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Aerosolized prostacyclin compared to placebo for acute respiratory distress syndrome (ARDS)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007733.pub3/full#CD007733-tbl-0001">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD007733.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD007733-note-0001">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD007733-note-0007">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD007733-note-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="ms#CD007733-note-0003">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD007733-note-0002">Русский</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007733\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007733\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007733\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007733\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007733\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007733\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007733\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007733\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007733\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007733\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007733\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007733\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007733\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007733\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007733\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007733\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007733\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007733\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=Nio3SV1W&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007733.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD007733.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD007733.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD007733.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007733.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"/> <span class="taglib-text hide-accessible">Sign In</span> </span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740729156900"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD007733.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"/> <span class="taglib-text hide-accessible">Sign In</span> </span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740729156903"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD007733.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918ed6058d77f55b',t:'MTc0MDcyOTE1Ny4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 